WO2007119881A1 - A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the ybda gene - Google Patents
A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the ybda gene Download PDFInfo
- Publication number
- WO2007119881A1 WO2007119881A1 PCT/JP2007/058571 JP2007058571W WO2007119881A1 WO 2007119881 A1 WO2007119881 A1 WO 2007119881A1 JP 2007058571 W JP2007058571 W JP 2007058571W WO 2007119881 A1 WO2007119881 A1 WO 2007119881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- amino acid
- coli
- bacterium
- ybda
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
- C12P13/222—Phenylalanine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
- C12P13/227—Tryptophan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/24—Proline; Hydroxyproline; Histidine
Definitions
- the present invention relates to the microbiological industry, and specifically to a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family which has been modified to attenuate expression of the ybdA gene.
- L-amino acids are industrially produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, or mutants thereof. Typically, the microorganisms are modified to enhance production yields of L-amino acids.
- Another way to enhance L-amino acid production yields is to attenuate expression of a gene or several genes involved in degradation of the target L-amino acid, genes diverting the precursors of the target L-amino acid from the L-amino acid biosynthetic pathway, genes involved in the redistribution of carbon, nitrogen, and phosphate fluxes, and genes coding for toxins etc.
- the enterobactin system for iron transport in Escherichia coli is well characterized, with the exception of the mechanism of enterobactin secretion to the extracellular environment.
- Escherichia coli membrane protein P43(YbdA) encoded by ybdA in the chromosomal region of genes involved in enterobactin synthesis, shows strong homology to the 12-transmembrane segment major facilitator superfamily of export pumps.
- P43(YbdA) is a critical component of the E. coli enterobactin secretion machinery and the rationale behind its previous designation as entS reflects its biological function (Eis . L. Furrer, et al, MoI. Microbiol, 44(5): 1225-34(2002)). But currently, there have been no reports of attenuating expression of the ybdA gene for the purpose of producing L-amino acids.
- Objects of the present invention include enhancing the productivity of L-amino acid-producing strains and providing a method for producing an L-amino acid using these strains.
- L-amino acids such as L-threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L- valine, L-histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, L-arginine, L- phenylalanine, L-tyrosine, and L-tryptophan.
- L-amino acids such as L-threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L- valine, L-histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, L
- the present invention provides a bacterium of the Enterobacteriaceae family having an increased ability to produce amino acids, such as L-threonine, L-lysine, L- cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, L-arginine, L-phenylalanine, L-tyrosine, and L-tryptophan.
- amino acids such as L-threonine, L-lysine, L- cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glu
- L-amino acid is selected from the group consisting of an aromatic L- amino acid and a non-aromatic L-amino acid.
- non-aromatic L-amino acid is selected from the group consisting of L- threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L- histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L- glutamic acid, L-proline, and L-arginine.
- L-amino acid is selected from the group consisting of an aromatic L- amino acid and a non-aromatic L-amino acid.
- aromatic L-amino acid is selected from the group consisting of L- phenylalanine, L-tyrosine, and L-tryptophan.
- non-aromatic L-amino acid is selected from the group consisting of L- threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L- histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L- glutamic acid, L-proline, and L-arginine.
- the bacterium of the present invention is an L-amino acid-producing bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified to attenuate expression of the ybdA gene.
- L-amino acid-producing bacterium means a bacterium which has an ability to produce and excrete an L-amino acid into a medium, when the bacterium is cultured in the medium.
- L-amino acid-producing bacterium as used herein also means a bacterium which is able to produce and cause accumulation of an L-amino acid in a culture medium in an amount larger than a wild-type or parental strain of the bacterium, for example, E. coli, such as E. coli K- 12, and preferably means that the bacterium is able to cause accumulation in a medium of an amount not less than 0.5 g/L, more preferably not less than 1.0 g/L, of the target L-amino acid.
- L-amino acid includes L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L- proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.
- aromatic L-amino acid includes L-phenylalanine, L-tyrosine, and L- tryptophan.
- non-aromatic L-amino acid includes L-threonine, L-lysine, L- cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, and L- arginine.
- L-threonine L-lysine, L-cysteine, L-leucine, L-histidine, L-glutamic acid, L- phenylalanine, L-tryptophan, L-proline, and L-arginine are particularly preferred.
- the Enterobacteriaceae family includes bacteria belonging to the genera Escherichia, Enter obacter, Erwinia, Klebsiella, Pantoea, Photorhabdus, Providencia, Salmonella, Serratia, Shigella, Morganella, Yersinia, etc. Specifically, those classified into the Enterobacteriaceae according to the taxonomy used by the NCBI (National Center for Biotechnology Information) database
- a bacterium belonging to the genus Escherichia means that the bacterium is classified into the genus Escherichia according to the classification known to a person skilled in the art of microbiology.
- a bacterium belonging to the genus Escherichia as used in the present invention include, but are not limited to, Escherichia coli (E. coif).
- the bacterium belonging to the genus Escherichia that can be used in the present invention is not particularly limited, however for example, bacteria described by Neidhardt, F.C. et al. (Escherichia coli and Salmonella typhimurium, American Society for Microbiology, Washington D. C, 1208, Table 1) are encompassed by the present invention.
- a bacterium belonging to the genus Pantoea means that the bacterium is classified as the genus Pantoea according to the classification known to a person skilled in the art of microbiology.
- Some species o ⁇ Enter obacter agglomerans have been recently re-classified into Pantoea agglomerans, Pantoea ananatis, Pantoea stewartii or the like, based on the nucleotide sequence analysis of 16S rRNA, etc. (Int. J. Syst. BacterioL, 43, 162-173 (1993)).
- bacteria has been modified to attenuate expression of the ybdA gene means that the bacterium has been modified in such a way that the modified bacterium contains a reduced amount of the YbdA protein as compared with an unmodified bacterium, or the modified bacterium is unable to synthesize the YbdA protein.
- the phrase "bacterium has been modified to attenuate expression of the ybdA gene” also may mean that the target gene in the bacterium is modified in such a way that the modified gene encodes a mutant YbdA protein which has a decreased activity.
- a P43(YbdA)-null mutation was created and siderophore nutrition assays, performed with a panel of E. coli strains expressing one or more outer membrane receptors for enterobactin-related compounds, demonstrated that the P43(YbdA) mutant was unable to secrete enterobactin efficiently.
- Products released from the mutant strain were identified with thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC), revealing that the P43 mutant secretes little, if any, enterobactin, but elevated levels of enterobactin breakdown products 2,3- dihydroxybenzoylserine (DHBS) monomer, dimer, and trimer (J. L.
- the reduced or absent activity of the YbdA protein in the bacterium according to the present invention can be determined when compared to the parent unmodified bacterium.
- activation of the ybdA gene means that the modified gene encodes a completely inactive protein. It is also possible that the modified DNA region is unable to naturally express the gene due to the deletion of a part of the gene or of the gene entirely, the shifting of the reading frame of the gene, the introduction of missense/nonsense mutation(s), or the modification of an adjacent region of the gene, including sequences controlling gene expression, such as promoter(s), enhancer(s), attenuator(s), ribosome- binding site(s), etc.
- the level of gene expression can be estimated by measuring the amount of mRNA transcribed from the gene using various known methods including Northern blotting, quantitative RT-PCR, and the like.
- the amount of the protein coded by the gene can be measured by known methods including SDS-PAGE followed by immunoblotting assay (Western blotting analysis) and the like.
- the ybdA gene encodes the YbdA protein (synonyms - EntS, B0591).
- the ybdA gene of E. coli (nucleotides 621,523 to 622,773 in the GenBank accession number NC_000913.2; gi:16128574; SEQ ID NO: 1) is located between the gene fepD and the gene fepB on the chromosome of E. coli strain K-12.
- the nucleotide sequence of ih&ybdA gene and the amino acid sequence of YbdA encoded by the ybdA gene are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
- the ybdA gene to be inactivated on the chromosome is not limited to the gene shown in SEQ ID No:l, but may include genes homologous to SEQ ID No:l encoding a variant protein of the YbdA protein.
- variant protein as used in the present invention means a protein which has changes in the sequence, whether they are deletions, insertions, additions, or substitutions of amino acids, but still maintains the activity of the product as the YbdA protein. The number of changes in the variant protein depends on the position in the three dimensional structure of the protein or the type of amino acid residues.
- a conservative mutation is a mutation wherein substitution takes place mutually among Phe, Trp, Tyr, if the substitution site is an aromatic amino acid; among Leu, He, VaI, if the substitution site is a hydrophobic amino acid; between GIn, Asn, if it is a polar amino acid; among Lys, Arg, His, if it is a basic amino acid; between Asp, GIu, if it is an acidic amino acid; and between Ser, Thr, if it is an amino acid having a hydroxyl group.
- Typical conservative mutations are conservative substitutions.
- substitutions that are considered to be conservative include: substitution of Ala with Ser or Thr; substitution of Arg with GIn, His, or Lys; substitution of Asn with GIu, GIn, Lys, His, or Asp; substitution of Asp with Asn, GIu, or GIn; substitution of Cys with Ser or Ala; substitution of GIn with Asn, GIu, Lys, His, Asp, or Arg; substitution of GIu with GIy, Asn, GIn, Lys, or Asp; substitution of GIy with Pro; substitution of His with Asn, Lys, GIn, Arg, or Tyr; substitution of He with Leu, Met, VaI, or Phe; substitution of Leu with He, Met, VaI, or Phe; substitution of Lys with Asn, GIu, GIn, His, or Arg; substitution of Met with He, Leu, VaI, or Phe; substitution of Phe with Trp, Tyr, Met, He, or Leu; substitution of Ser with Thr or Ala;
- Substitutions, deletions, insertions, additions, or inversions and the like of the amino acids described above include naturally occurred mutations (mutant or variant) depending on differences in species, or individual differences of microorganisms that retain the ybdA gene.
- Such a gene can be obtained by modifying the nucleotide sequence shown in SEQ ID NO: 1 using, for example, site- directed mutagenesis, so that the site-specific amino acid residue in the protein encoded includes substitutions, deletions, insertions, or additions.
- the protein variant encoded by the ybdA gene may be one which has a homology of not less than 80%, preferably not less than 90%, and most preferably not less than 95%, with respect to the entire amino acid sequence shown in SEQ ID NO. 2, as long as the activity of the YbdA protein prior to inactivation is maintained.
- Homology between two amino acid sequences can be determined using the well- known methods, for example, the computer program BLAST 2.0, which calculates three parameters: score, identity and similarity.
- the ybdA gene may be a variant which hybridizes under stringent conditions with the nucleotide sequence shown in SEQ ID NO: 1, or a probe which can be prepared from the nucleotide sequence under stringent conditions, provided that it encodes a functional YbdA protein prior to inactivation.
- Stringent conditions include those under which a specific hybrid, for example, a hybrid having homology of not less than 60%, preferably not less than 70%, more preferably not less than 80%, still more preferably not less than 90%, and most preferably not less than 95%, is formed and a non-specific hybrid, for example, a hybrid having homology lower than the above, is not formed.
- stringent conditions are exemplified by washing one time or more, preferably two or three times at a salt concentration of 1 xSSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS at 6O 0 C.
- Duration of washing depends on the type of membrane used for blotting and, as a rule, should be what is recommended by the manufacturer.
- the recommended duration of washing for the HybondTM N+ nylon membrane (Amersham) under stringent conditions is 15 minutes.
- washing may be performed 2 to 3 times.
- the length of the probe may be suitably selected, depending on the hybridization conditions, in this specific case, it may be about 100 bp to 1 kbp.
- Expression of the ybdA gene can be attenuated by introducing a mutation into the gene on the chromosome so that the intracellular activity of protein encoded by the gene is decreased as compared with an unmodified strain.
- a mutation on the gene can be replacement of one base or more to cause amino acid substitution in the protein encoded by the gene (missense mutation), introduction of a stop codon (nonsense mutation), deletion of one or two bases to cause a frame shift, insertion of a drug-resistance gene, or deletion of a part of the gene or the entire gene (Qiu, Z. and Goodman, M.F., J. Biol. Chem., 272, 8611-8617 (1997); Kwon, D. H. et al, J.
- Expression of the ybdA gene can also be attenuated by modifying an expression regulating sequence such as the promoter, the Shine-Dalgarno (SD) sequence, etc. (WO95/34672, Carrier, T.A. and Keasling, J.D., Biotechnol Prog 15, 58-64 (1999)).
- SD Shine-Dalgarno
- the following methods may be employed to introduce a mutation by gene recombination.
- a mutant gene encoding a mutant protein having a decreased activity is prepared, and a bacterium to be modified is transformed with a DNA fragment containing the mutant gene.
- the native gene on the chromosome is replaced with the mutant gene by homologous recombination, and the resulting strain is selected.
- Such gene replacement by homologous recombination can be conducted by employing a linear DNA, which is known as "Red-driven integration" (Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci.
- Expression of the gene can also be attenuated by insertion of a transposon or an IS factor into the coding region of the gene (U.S. Patent No. 5,175,107), or by conventional methods, such as mutagenesis with UV irradiation or nitrosoguanidine (N-methyl-N'-nitro- N-nitrosoguanidine) .
- Inactivation of the gene can also be performed by conventional methods, such as by mutagenesis using UV irradiation or nitrosoguanidine (N-methyl-N'-nitro-N- nitrosoguanidine), site-directed mutagenesis, gene disruption using homologous recombination, or/and insertion-deletion mutagenesis (Yu, D. et al., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 5978-83 and Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 6640-45) also called "Red-driven integration".
- the presence or absence of the ybdA gene on the chromosome of a bacterium can be detected by well-known methods, including PCR, Southern blotting, and the like, hi addition, the level of gene expression can be estimated by measuring the amount of mRNA transcribed from the gene using various well-known methods, including Northern blotting, quantitative RT-PCR, and the like.
- the amount or molecular weight of the protein encoded by the gene can be measured by well-known methods, including SDS-PAGE followed by immunoblotting assay (Western blotting analysis), and the like.
- Methods for preparation of plasmid DNA, digestion and ligation of DNA, transformation, selection of an oligonucleotide as a primer, and the like may be ordinary methods well-known to one skilled in the art. These methods are described, for instance, in Sambrook, J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning: A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989).
- bacteria which are able to produce either an aromatic or a non-aromatic L-amino acids may be used.
- the bacterium of the present invention can be obtained by attenuating expression of the ybdA gene in a bacterium which inherently has the ability to produce an L-amino acid.
- the bacterium of present invention can be obtained by imparting the ability to produce L-amino acids to a bacterium already having the attenuated expression of the ybdA gene.
- Examples of parent strains for deriving the L-threonine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli TDH-6/pVIC40 (VKPM B-3996) (U.S. Patent No. 5, 175, 107, U.S. Patent No. 5,705,371), E. coli 472T23/pYN7 (ATCC 98081) (U.S. Patent No.5,631,157), E. coli NRRL-21593 (U.S. Patent No. 5,939,307), E. coli FERM BP-3756 (U.S. Patent No. 5,474,918), E.
- E. coli TDH-6/pVIC40 VKPM B-3996
- E.S. Patent No. 5, 175, 107, U.S. Patent No. 5,705,371 E. coli 472T23/pYN7 (ATCC 98081)
- E. coli FERM BP-3519 and FERM BP-3520 U.S. Patent No. 5,376,538, E. coli MG442 (Gusyatiner et al., Genetika (in Russian), 14, 947-956 (1978)), E. coli VL643 and VL2055 (EP 1149911 A), and the like.
- the strain TDH-6 is deficient in the thrC gene, as well as being sucrose- assimilative, and the HvA gene has a leaky mutation. This strain also has a mutation in the rhtA gene, which imparts resistance to high concentrations of threonine or homoserine.
- the strain B-3996 contains the plasmid pVIC40 which was obtained by inserting a thrA*BC operon which includes a mutant thrA gene into a RSFlOlO-derived vector. This mutant thrA gene encodes aspartokinase homoserine dehydrogenase I which has substantially desensitized feedback inhibition by threonine.
- the strain B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (USD, 117105 Moscow, Nagatinskaya Street, 3 -A) under the accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow 1, Dorozhny proezd. 1) on April 7, 1987 under the accession number VKPM B-3996.
- VKPM Russian National Collection of Industrial Microorganisms
- E. coli VKPM B-5318 (EP 0593792B) may also be used as a parent strain for deriving L-threonine-producing bacteria of the present invention.
- the strain B-5318 is prototrophic with regard to isoleucine, and a temperature-sensitive lambda-phage Cl repressor and PR promoter replaces the regulatory region of the threonine operon in plasmid pVIC40.
- the strain VKPM B-5318 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM) on May 3, 1990 under accession number of VKPM B-5318.
- the bacterium of the present invention is additionally modified to enhance expression of one or more of the following genes: the mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine; the thrB gene which codes for homoserine kinase; the thrC gene which codes for threonine synthase; the rhtA gene which codes for a putative transmembrane protein; the asd gene which codes for aspartate- ⁇ -semialdehyde dehydrogenase; and the aspC gene which codes for aspartate aminotransferase (aspartate transaminase);
- the mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine
- the thrB gene which codes for homoserine kinase
- the thrC gene which codes for thre
- the thrA gene which encodes aspartokinase homoserine dehydrogenase I of Escherichia coli has been elucidated (nucleotide positions 337 to 2799, GenBank accession no.NC_000913.2, gi: 49175990).
- the thrA gene is located between the thrL and thrB genes on the chromosome of E. coli K-12.
- the thrB gene which encodes homoserine kinase of Escherichia coli has been elucidated (nucleotide positions 2801 to 3733, GenBank accession no.NC_000913.2, gi: 49175990).
- the thrB gene is located between the thrA and thrC genes on the chromosome of E. coli K- 12.
- the thrC gene which encodes threonine synthase of Escherichia coli has been elucidated (nucleotide positions 3734 to 5020, GenBank accession no.NC_000913.2, gi: 49175990).
- the thrC gene is located between the thrB gene and the yaa ⁇ open reading frame on the chromosome of E. coli K- 12. All three genes function as a single threonine operon. To enhance expression of the threonine operon, the attenuator region which affects the transcription is removed from the operon (WO2005/049808, WO2003/097839).
- a mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine, as well as the thrB and thrC genes can be obtained as one operon from the well-known plasmid pVIC40 which is present in the threonine producing E. coli strain VKPM B-3996. Plasmid pVIC40 is described in detail in U.S. Patent No. 5,705,371.
- the rhtA gene exists at 18 min on the E. coli chromosome close to the glnHPQ operon, which encodes components of the glutamine transport system.
- the rhtA gene is identical to ORFl (ybiF gene, nucleotide positions 764 to 1651, GenBank accession number AAA218541, gi:440181) and is located between the pexB and ompX genes.
- the unit expressing a protein encoded by the ORFl has been designated the rhtA gene (rht: resistance to homoserine and threonine).
- the asd gene of E. coli has already been elucidated (nucleotide positions 3572511 to 3571408, GenBank accession no. NC_000913.1, gi:16131307), and can be obtained by PCR (polymerase chain reaction; refer to White, TJ. et al, Trends Genet., 5, 185 (1989)) utilizing primers prepared based on the nucleotide sequence of the gene.
- the asd genes of other microorganisms can be obtained in a similar manner.
- the aspC gene of E. coli has already been elucidated (nucleotide positions 983742 to 984932, GenBank accession no. NC_000913.1, gi: 16128895), and can be obtained by PCR.
- the aspC genes of other microorganisms can be obtained in a similar manner.
- L-lysine-producing bacteria belonging to the genus Escherichia include mutants having resistance to an L-lysine analogue.
- the L-lysine analogue inhibits growth of bacteria belonging to the genus Escherichia, but this inhibition is fully or partially desensitized when L-Iy sine coexists in a medium.
- Examples of the L-lysine analogue include, but are not limited to, oxalysine, lysine hydroxamate, S-(2-aminoethyl)- L-cysteine (AEC), ⁇ -methyllysine, ⁇ -chlorocaprolactam, and so forth.
- Mutants having resistance to these lysine analogues can be obtained by subjecting bacteria belonging to the genus Escherichia to a conventional artificial mutagenesis treatment.
- bacterial strains useful for producing L-lysine include Escherichia coli AJl 1442 (FERM BP-1543, NRRL B-12185; see U.S. Patent No. 4,346,170) and Escherichia coli VL611. In these microorganisms, feedback inhibition of aspartokinase by L-lysine is desensitized.
- the strain WC 196 may be used as an L-lysine producing bacterium of Escherichia coli. This bacterial strain was bred by conferring AEC resistance to the strain W3110, which was derived from Escherichia coli K- 12. The resulting strain was designated Escherichia coli AJl 3069 and was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on December 6, 1994 and received an accession number of FERM P- 14690. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and received an accession number of FERM BP-5252 (U.S. Patent No. 5,827,698).
- Examples of parent strains for deriving L-lysine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- lysine biosynthetic enzyme are enhanced.
- genes include, but are not limited to, genes encoding dihydrodipicolinate synthase (dapA), aspartokinase (lysC), dihydrodipicolinate reductase (dapB), diaminopimelate decarboxylase (lysA), diaminopimelate dehydrogenase (ddh) (U.S. Patent No.
- ppc phosphoenolpyrvate carboxylase
- aspartate semialdehyde dehydrogenease aspartase
- aspA aspartase
- the parent strains may have increased expression of the gene involved in energy efficiency (cyo) (EP 1170376 A), the gene encoding nicotinamide nucleotide transhydrogenase (pntAB) (U.S. Patent No. 5,830,716), iheybjE gene (WO2005/073390), or combinations thereof.
- Examples of parent strains for deriving L-lysine-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine.
- Examples of the enzymes that catalyze a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine include homoserine dehydrogenase, lysine decarboxylase (U.S. Patent No. 5,827,698), and the malic enzyme (WO2005/010175).
- L-cvsteine-producing bacteria include homoserine dehydrogenase, lysine decarboxylase (U.S. Patent No. 5,827,698), and the malic enzyme (WO2005/010175).
- parent strains for deriving L-cysteine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli JMl 5 which is transformed with different cysE alleles coding for feedback- resistant serine acetyltransferases (U.S. Patent No. 6,218,168, Russian patent application 2003121601); E. coli W3110 having over-expressed genes which encode proteins suitable for secreting substances toxic for cells (U.S. Patent No. 5,972,663); E. coli strains having lowered cysteine desulfohydrase activity (JPl 1155571 A2); E. coli W3110 with increased activity of a positive transcriptional regulator for cysteine regulon encoded by the cysB gene (WO0127307A1), and the like.
- E. coli JMl 5 which is transformed with different cysE alleles coding for feedback- resistant serine acety
- parent strains for deriving L-leucine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strains resistant to leucine (for example, the strain 57 (VKPM B-7386, U.S. Patent No. 6,124,121)) or leucine analogs including ⁇ -2-thienylalanine, 3-hydroxyleucine, 4-azaleucine, 5,5,5-trifluoroleucine (JP 62-34397 B and JP 8-70879 A); E. coli strains obtained by the gene engineering method described in WO96/06926; E. coli H-9068 (JP 8- 70879 A), and the like.
- E. coli strains resistant to leucine for example, the strain 57 (VKPM B-7386, U.S. Patent No. 6,124,121)
- leucine analogs including ⁇ -2-thienylalanine, 3-hydroxyleucine, 4-
- the bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-leucine biosynthesis.
- genes of the leuABCD operon which are preferably represented by a mutant leuA gene coding for isopropylmalate synthase which is freed from feedback inhibition by L-leucine (US Patent No. 6,403,342).
- the bacterium of the present invention may be improved by enhancing the expression of one or more genes coding for proteins which excrete L-amino acid from the bacterial cell. Examples of such genes include the b2682 and b2683 genes (ygaZH genes) (EP 1239041 A2).
- Examples of parent strains for deriving L-histidine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strain 24 (VKPM B-5945, RU2003677); E. coli strain 80 (VKPM B-7270, RU2119536); E. coli NRRL B-12116 - B12121 (U.S. Patent No. 4,388,405); E. coli H- 9342 (FERM BP-6675) and H-9343 (FERM BP-6676) (U.S. Patent No. 6,344,347); E. coli H-9341 (FERM BP-6674) (EP 1085087); E.
- E. coli strain 24 VKPM B-5945, RU2003677
- E. coli strain 80 VKPM B-7270, RU2119536
- E. coli NRRL B-12116 - B12121 U.S. Patent No. 4,388,40
- Examples of parent strains for deriving L-histidine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L-histidine biosynthetic enzyme are enhanced.
- genes include genes encoding ATP phosphoribosyltransferase (hisG), phosphoribosyl AMP cyclohydrolase (hisl), phosphoribosyl-ATP pyrophosphohydrolase (hisIE), phosphoribosylformimino-5- arninoimidazole carboxamide ribotide isomerase (hisA), amidotransferase (hisH), histidinol phosphate aminotransferase (hisC), histidinol phosphatase (hisB), histidinol dehydrogenase (hisD), and so forth.
- hisG phosphoribosyltransferase
- hisl phosphoribosyl AMP cyclohydrolase
- hisIE phosphoribosyl-ATP pyrophosphohydrolase
- hisA phosphoribosylformimino-5- arninoimidazole carboxamide ribotide isomerase
- strains having an L-histidine-producing ability include E. coli FERM P-5038 and 5048 which have been introduced with a vector carrying a DNA encoding an L-histidine-biosynthetic enzyme (JP 56-005099 A), E. coli strains introduced with rht, a gene for an amino acid-export (EPl 016710A), E. coli 80 strain imparted with sulfaguanidine, DL- 1 ,2,4-triazole-3 -alanine, and streptomycin-resistance (VKPM B-7270, Russian Patent No. 2119536), and so forth.
- JP 56-005099 A E. coli strains introduced with rht, a gene for an amino acid-export
- EPl 016710A a gene for an amino acid-export
- Examples of parent strains for deriving L-glutamic acid-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli VL334thrC + (EP 1172433).
- E. coli VL334 (VKPM B-1641) is an L- isoleucine and L-threonine auxotrophic strain having mutations in thrC and UvA genes (U.S. Patent No. 4,278,765).
- a wild-type allele of the thrC gene was transferred by the method of general transduction using a bacteriophage Pl which was grown on wild-type E. coli K12 (VKPM B-7) cells.
- an L-isoleucine auxotrophic strain VL334thrC + (VKPM B-8961), which is able to produce L-glutamic acid, was obtained.
- parent strains for deriving the L-glutamic acid-producing bacteria of the present invention include, but are not limited to, strains which are deficient in ⁇ - ketoglutarate dehydrogenase activity, or strains in which one or more genes encoding an L- glutamic acid biosynthetic enzyme are enhanced.
- genes involved in L- glutamic acid biosynthesis include genes encoding glutamate dehydrogenase (gdhA), glutamine synthetase (glnA), glutamate synthetase (gltAB), isocitrate dehydrogenase (icdA), aconitate hydratase ⁇ acnA, acnB), citrate synthase (gltA), phosphoenolpyruvate carboxylase (ppc), pyruvate carboxylase (pyc), pyruvate dehydrogenase (aceEF, ipdA), pyruvate kinase (pykA,pykF), phosphoenolpyruvate synthase (ppsA), enolase (eno), phosphoglyceromutase (pgmA, pgml), phosphoglycerate kinase (pgk), glyceraldeh
- strains modified so that expression of the citrate synthetase gene, the phosphoenolpyruvate carboxylase gene, and/or the glutamate dehydrogenase gene is/are enhanced include those disclosed in EP1078989A, EP955368A, and EP952221A.
- strains which have been modified so that expression of the citrate synthetase gene and/or the phosphoenolpyruvate carboxylase gene are reduced, and/or/are deficient in ⁇ -ketoglutarate dehydrogenase activity include those disclosed in EP1078989A, EP955368A, and EP952221A.
- Examples of parent strains for deriving the L-glutamic acid-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes synthesis of a compound other than L-glutamic acid by branching off from an L-glutamic acid biosynthesis pathway.
- Such enzymes include isocitrate lyase (aceA), ⁇ -ketoglutarate dehydrogenase (sucA), phosphotransacetylase (pt ⁇ ), acetate kinase (ack), acetohydroxy acid synthase (UvG), acetolactate synthase (UvI), formate acetyltransferase (pfl), lactate dehydrogenase (Idh), and glutamate decarboxylase (gadAB).
- aceA isocitrate lyase
- sucA ⁇ -ketoglutarate dehydrogenase
- pt ⁇ phosphotransacetylase
- ack acetate kinase
- UvG acetohydroxy acid synthase
- UvI acetolactate synthase
- pfl lactate dehydrogenase
- Idh lactate dehydrogenase
- glutamate decarboxylase
- E. coli W3110sucA::Kmr is a strain obtained by disrupting the ⁇ -ketoglutarate dehydrogenase gene (hereinafter referred to as "sucA gene") of E. coli W3110. This strain is completely deficient in ⁇ -ketoglutarate dehydrogenase.
- L-glutamic acid-producing bacteria include those which belong to the genus Escherichia and have resistance to an aspartic acid antimetabolite. These strains can also be deficient in ⁇ -ketoglutarate dehydrogenase activity and include, for example, E. coli AJ13199 (FERM BP-5807) (U.S. Patent No. 5.908,768), FFRM P-12379, which additionally has a low L-glutamic acid decomposing ability (U.S. Patent No. 5,393,671); AJ13138 (FERM BP-5565) (U.S. Patent No. 6,110,714), and the like.
- L-glutamic acid-producing bacteria examples include mutant strains belonging to the genus Pantoea which are deficient in ⁇ -ketoglutarate dehydrogenase activity or have decreased ⁇ -ketoglutarate dehydrogenase activity, and can be obtained as described above.
- Such strains include Pantoea ananatis AJ13356. (U.S. Patent No. 6,331,419).
- Pantoea ananatis AJ13356 was deposited at the National Institute of Bioscience and Human- Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on February 19, 1998 under an accession number of FERM P- 16645. It was then converted to an international deposit under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP- 6615.
- Pantoea ananatis AJ13356 is deficient in ⁇ -ketoglutarate dehydrogenase activity as a result of disruption of the ⁇ KGDH-El subunit gene (sucA).
- the above strain was identified as Enterobacter agglomerans when it was isolated and deposited as Enterobacter agglomerans AJl 3356.
- Pantoea ananatis on the basis of nucleotide sequencing of 16S rRNA and so forth.
- AJ13356 was deposited at the aforementioned depository as Enterobacter agglomerans, for the purposes of this specification, they are described as Pantoea ananatis.
- Examples of parent strains for deriving L-phenylalanine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli AJ12739 (tyrA::TnlO, tyrR) (VKPM B-8197); E. coli HW1089 (ATCC 55371) harboring the mutant pheA34 gene (U.S. Patent No. 5,354,672); E. coli MWEC101-b (KR8903681); E. coli NPvRL B-12141, NRRL B-12145, NRRL B-12146 and NRRL B-12147 (U.S. Patent No. 4,407,952).
- E. coli AJ12739 tyrA::TnlO, tyrR
- E. coli HW1089 ATCC 55371 harboring the mutant pheA34 gene (U.S. Patent No. 5,354,672)
- E. coli K-12 [W3110 (tyrA)/pPHAB (FERM BP-3566), E. coli K-12 [W3110 (tyrA)/pPHAD] (FERM BP- 12659), E. coli K-12 [W3110 (tyrA)/pPHATerm] (FERM BP-12662) and E. coli K-12 [W3110 (tyrA)/pBR-aroG4, pACMAB] named as AJ 12604 (FERM BP-3579) may be used (EP 488424 Bl).
- L-phenylalanine producing bacteria belonging to the genus Escherichia with an enhanced activity of the protein encoded by the yedA gene or the yddG gene may also be used (U.S. patent applications 2003/0148473 Al and 2003/0157667 Al).
- parent strains for deriving the L-tryptophan-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli JP4735/pMU3028 (DSM10122) and JP6015/pMU91 (DSM10123) which is deficient in the tryptophanyl-tRNA synthetase encoded by mutant trpS gene (U.S. Patent No. 5,756,345); E.
- coli SVl 64 (pGH5) having a serA allele encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine and a trpE allele encoding anthranilate synthase free from feedback inhibition by tryptophan (U.S. Patent No. 6,180,373); E. coli AGX17 (pGX44) (NRRL B-12263) and AGX6(pGX50)aroP (NRRL B-12264) deficient in the enzyme tryptophanase (U.S. Patent No. 4,371,614); E.
- coli AGX17/pGX50,pACKG4-pps in which a phosphoenolpyruvate-producing ability is enhanced (WO9708333, U.S. Patent No. 6,319,696), and the like may be used.
- L- tryptophan-producing bacteria belonging to the genus Escherichia with an enhanced activity of the identified protein encoded by and the yedA gene or the yddG gene may also be used (U.S. patent applications 2003/0148473 Al and 2003/0157667 Al).
- Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains in which one or more activities of the enzymes selected from anthranilate synthase, phosphoglycerate dehydrogenase, and tryptophan synthase are enhanced.
- the anthranilate synthase and phosphoglycerate dehydrogenase are both subject to feedback inhibition by L-tryptophan and L-serine, so that a mutation desensitizing the feedback inhibition may be introduced into these enzymes.
- Specific examples of strains having such a mutation include a E. coli SVl 64 which harbors desensitized anthranilate synthase and a transformant strain obtained by introducing into the E. coli SV164 the plasmid ⁇ GH5 (WO 94/08031), which contains a mutant serA gene encoding feedback-desensitized phosphoglycerate dehydrogenase.
- Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains into which the tryptophan operon which contains a gene encoding desensitized anthranilate synthase has been introduced (JP 57-71397 A, JP 62-244382 A, U.S. Patent No. 4,371,614).
- L-tryptophan-producing ability may be imparted by enhancing expression of a gene which encodes tryptophan synthase.
- the tryptophan synthase consists of ⁇ and ⁇ subunits which are encoded by the trpA and trpB genes, respectively.
- L-tryptophan-producing ability may be improved by enhancing expression of the isocitrate lyase-malate synthase operon (WO2005/103275).
- Examples of parent strains for deriving L-proline-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli 702ilvA (VKPM B-8012) which is deficient in the HvA gene and is able to produce L-proline (EP 1172433).
- the bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-proline biosynthesis. Examples of such genes for L-proline producing bacteria include the proB gene coding for glutamate kinasewhich has feedback inhibition by L-proline desensitized (DE Patent 3127361).
- the bacterium of the present invention may be improved by enhancing the expression of one or more genes coding for proteins excreting L-amino acid from bacterial cell.
- genes are exemplified by the b2682 and b2683 genes (ygaZH genes) (EP 1239041 A2).
- parent strains for deriving L-arginine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strain 237 (VKPM B-7925) (U.S. Patent Application 2002/058315 Al) and its derivative strains harboring mutant N-acetylglutamate synthase ( Russian Patent Application No. 2001112869), E. coli strain 382 (VKPM B-7926) (EPl 170358A1), an arginine-producing strain into which argA gene encoding N-acetylglutamate synthetase is introduced therein (EPl 170361 Al), and the like.
- Examples of parent strains for deriving L-arginine producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- arginine biosynthetic enzyme are enhanced.
- examples of such genes include genes encoding N-acetylglutamyl phosphate reductase (argC), ornithine acetyl transferase (argJ), N-acetylglutamate kinase (argB), acetylo ⁇ iithine transaminase (argD), ornithine carbamoyl transferase (argF), argininosuccinic acid synthetase (argG), argininosuccinic acid lyase (argH), and carbamoyl phosphate synthetase ⁇ car AB).
- argC N-acetylglutamyl phosphate reductase
- argJ ornithine acety
- Example of parent strains for deriving L-valine-producing bacteria of the present invention include, but are not limited to, strains which have been modified to overexpress the UvGMEDA operon (U.S. Patent No. 5,998,178). It is desirable to remove the region of the HvGMEDA operon which is required for attenuation so that expression of the operon is not attenuated by the L-valine that is produced. Furthermore, the UvA gene in the operon is desirably disrupted so that threonine deaminase activity is decreased.
- Examples of parent strains for deriving L-valine-producing bacteria of the present invention include also include mutants having a mutation of amino-acyl t-RNA synthetase (U.S. Patent No. 5,658,766).
- E. coli VL1970 which has a mutation in the UeS gene encoding isoleucine iRNA synthetase, can be used.
- E. coli VL 1970 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny Proezd, 1) on June 24, 1988 under accession number VKPM B-4411.
- mutants requiring lipoic acid for growth and/or lacking H + -ATPaSe can also be used as parent strains (WO96/06926).
- parent strains for deriving L-isoleucine producing bacteria of the present invention include, but are not limited to, mutants having resistance to 6- dimethylaminopurine (JP 5-304969 A), mutants having resistance to an isoleucine analogue such as thiaisoleucine and isoleucine hydroxamate, and mutants additionally having resistance to DL-ethionine and/or arginine hydroxamate (JP 5-130882 A).
- recombinant strains transformed with genes encoding proteins involved in L- isoleucine biosynthesis can also be used as parent strains (JP 2-458 A, FR 0356739, and U.S. Patent No. 5,998,178).
- the method of the present invention is a method for producing an L-amino acid comprising cultivating the bacterium of the present invention in a culture medium to produce and excrete the L-amino acid into the medium, and collecting the L-amino acid from the medium.
- the cultivation, collection, and purification of an L-amino acid from the medium and the like may be performed in a manner similar to conventional fermentation methods wherein an amino acid is produced using a bacterium.
- the chosen culture medium may be either a synthetic or natural medium, so long as it includes a carbon source and a nitrogen source and minerals and, if necessary, appropriate amounts of nutrients which the bacterium requires for growth.
- the carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the mode of assimilation of the chosen microorganism, alcohol, including ethanol and glycerol, may be used.
- As the nitrogen source various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, and digested fermentative microorganisms can be used.
- potassium monophosphate magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium chloride, and the like can be used.
- vitamins thiamine, yeast extract, and the like, can be used.
- the cultivation is preferably performed under aerobic conditions, such as by shaking and/or stirring with aeration, at a temperature of 20 to 40 °C, preferably 30 to 38 °C.
- the pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2.
- the pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 5-day cultivation leads to accumulation of the target L-amino acid in the liquid medium.
- solids such as cells can be removed from the liquid medium by centrifugation or membrane filtration, and then the L-amino acid can be collected and purified by ion-exchange, concentration, and/or crystallization methods.
- Figure 1 shows the relative positions of primers ybdAL and ybdAR on plasmid pACYC184, which is used for amplification of the cat gene.
- Figure 2 shows the construction of the chromosomal DNA fragment comprising the inactivated y ⁇ gene.
- Example 1 Construction of a strain with an inactivated ybdA gene.
- the ybdA gene was deleted by the method initially developed by Datsenko, K. A. and Wanner, B.L. (Proc. Natl. Acad. Sci. USA, 2000, 97(12), 6640-6645) called "Red- driven integration". According to this procedure, the PCR primers ybdAL (SEQ ID NO: 3) and ybdAR (SEQ ID NO: 4), which are complementary to both the region adjacent to the ybdA gene and the gene conferring antibiotic resistance, respectively, in the template plasmid, were constructed.
- the plasmid pACYC184 NBL Gene Sciences Ltd., UK
- GenBank/EMBL accession number X06403 was used as a template in the PCR reaction.
- Conditions for PCR were as follows: denaturation step:3 min at 95 0 C; profile for two first cycles: 1 min at 95 °C, 30 sec at 50 °C, 40 sec at 72 °C; profile for the last 25 cycles: 30 sec at 95 0 C, 30 sec at 54 °C, 40 sec at 72 0 C; final step: 5 min at 72 0 C.
- FIG. 1 An 1152 bp PCR product (Fig. 1) was obtained and purified in agarose gel and used for electroporation of E. coli MG 1655 (ATCC 700926), which contains the plasmid pKD46 having a temperature-sensitive replication.
- the plasmid pKD46 (Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12:6640-45) includes a 2,154 nucleotide (31088-33241) DNA fragment of phage ⁇ (GenBank accession No.
- the strain MG1655 can be obtained from American Type Culture Collection. (P.O. Box 1549 Manassas, VA 20108, U.S.A.).
- Electrocompetent cells were prepared as follows: E. coli MG1655/pKD46 was grown overnight at 30 °C in LB medium containing ampicillin (100 mg/1), and the culture was diluted 100 times with 5 ml of SOB medium (Sambrook et al, "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989)) containing ampicillin and L-arabinose (1 mM). The cells were grown with aeration at 30 °C to an OD 600 of «0.6 and then were made electrocompetent by concentrating 100-fold and washing three times with ice-cold deionized H 2 O. Electroporation was performed using 70 ⁇ l of cells and «100 ng of PCR product.
- the mutants which have the ybdA gene deleted and are marked with the Cm resistance gene, were verified by PCR.
- Locus-specific primers ybdAl (SEQ ID NO: 5) and ybdA2 (SEQ ID NO: 6) were used in PCR for verification. Conditions for PCR verification were as follows: denaturation step: 3 min at 94 °C; profile for the 30 cycles: 30 sec at 94 0 C, 30 sec at 54 0 C, 1 min at 72 °C; final step: 7 min at 72 0 C.
- the PCR product obtained using the parental ybdA + strain MGl 655 as the template is 1420 bp in length.
- the PCR product obtained using the mutant strain as the template is 1249 nucleotides in length (Fig.2).
- the mutant strain was named MGl 655 ⁇ ybdA::cat.
- Example 2 Production of L-threonine by E. coli strain B-3996- ⁇ ybdA
- DNA fragments from the chromosome of the above-described E. coli MGl 655 ⁇ ybdA::cat were transferred to the threonine-producing E. coli strain VKPM B-3996 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain B-3996- ⁇ ybdA.
- the strain B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (USD, 117105 Moscow, Nagatinskaya Street 3 -A) under the accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 Dorozhny proezd, 1) under the accession number VKPM B- 3996.
- VKPM Russian National Collection of Industrial Microorganisms
- Both E. coli B-3996 and B-3996- ⁇ ybdA were grown for 18-24 hours at 37 0 C on L- agar plates.
- the strains were grown on a rotary shaker (250 rpm) at 32°C for 18 hours in 20x200-mm test tubes containing 2 ml of L-broth supplemented with 4% glucose.
- the fermentation medium was inoculated with 0.21 ml (10%) of seed material.
- the fermentation was performed in 2 ml of minimal medium for fermentation in 20x200-mm test tubes. Cells were grown for 65 hours at 32°C with shaking at 250 rpm.
- composition of the fermentation medium (g/1) was as follows:
- Glucose and magnesium sulfate were sterilized separately.
- CaCO 3 was sterilized by dry-heat at 180°C for 2 hours. The pH was adjusted to 7.0. The antibiotic was introduced into the medium after sterilization.
- Example 3 Production of L-lvsine by E. coli AJ11442- ⁇ ybdA
- DNA fragments from the chromosome of the above-described E. coli strain MG1655 ⁇ ybdA::cat can be transferred to the Iy sine-producing E. coli strain AJl 1442 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain AJl 1442- ⁇ ybdA strain.
- the strain AJ14442 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on May 1, 1981 and received an accession number of FERM P-5084. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on Octobe 29, 1987, and received an accession number of FERM BP- 1543.
- Both E. coli strains can be cultured in L-medium containing streptomycin (20 mg/1) at 37 0 C, and 0.3 ml of the obtained culture can be inoculated into 20 ml of the fermentation medium containing the required drugs in a 500- ml flask.
- the cultivation can be carried out at 37°C for 16 h by using a reciprocal shaker at the agitation speed of 115 rpm.
- the amounts of L-lysine and residual glucose in the medium can be measured by a known method (Biotech-analyzer AS210 manufactured by Sakura Seiki Co.). Then, the yield of L-lysine can be calculated relative to consumed glucose for each of the strains.
- composition of the fermentation medium (g/1) is as follows:
- the pH is adjusted to 7.0 by KOH and the medium is autoclaved at 115°C for 10 min. Glucose and MgSO 4 7H 2 O are sterilized separately. CaCO 3 is dry-heat sterilized at 180°C for 2 hours and added to the medium for a final concentration of 30 g/1.
- Example 4 Production of L-cysteine by E. coli JM15(ydeD> ⁇ ybdA
- DNA fragments from the chromosome of the above-described E. coli MGl 655 ⁇ ybdA::cat can be transferred to the E. coli L-cysteine-producing strain JM15(ydeD) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain JM15(ydeD)- ⁇ ybdA.
- E. coli JM15(ydeD) is a derivative of E. coli JM15 (US Patent No. 6,218,168), which can be transformed with DNA having the ydeD gene encoding a membrane protein, and is not involved in a biosynthetic pathway of any L-amino acid (U.S. Patent No. 5,972,663).
- the strain JMl 5 (CGSC# 5042) can be obtained from The Coli Genetic Stock Collection at the E. coli Genetic Resource Center, MCD Biology Department, Yale University (http://cgsc.biology.yale.edu/).
- DNA fragments from the chromosome of the above-described E. coli strain MG1655 ⁇ ybdA::cat can be transferred to the E. coli L-leucine-producing strain 57 (VKPM B-7386, US Patent No. 6,124,121) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain 57-pMW- ⁇ ybdA.
- the strain 57 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on May 19, 1997 under accession number VKPM B-7386.
- Both E. coli strains, 57 and 57- ⁇ ybdA can be cultured for 18-24 hours at 37°C on L- agar plates.
- the strains can be grown on a rotary shaker (250 rpm) at 32 0 C for 18 hours in 20x200-mm test tubes containing 2 ml of L-broth supplemented with 4% sucrose.
- the fermentation medium can be inoculated with 0.21 ml of seed material (10%).
- the fermentation can be performed in 2 ml of a minimal fermentation medium in 20x200-mm test tubes.
- Cells can be grown for 48-72 hours at 32°C with shaking at 250 rpm.
- composition of the fermentation medium (g/1) (pH 7.2) is as follows:
- DNA fragments from the chromosome of the above-described E. coli MG1655 ⁇ ybdA::cat can be transferred to the histidine-producing E. coli strain 80 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain strain 80- ⁇ ybdA.
- strain 80 has been described in Russian patent 2119536 and deposited in the Russian National Collection of Industrial Microorganisms ( Russian, 117545 Moscow, 1 Dorozhny proezd, 1) on October 15, 1999 under accession number VKPM B- 7270 and then converted to a deposit under the Budapest Treaty on July 12, 2004.
- composition of the fermentation medium (g/1) is as follows (pH 6.0):
- Glucose, proline, betaine and CaCO 3 are sterilized separately.
- the pH is adjusted to 6.0 before sterilization.
- Example 7 Production of L-glutamate by E. coli VL334thrC + - ⁇ vbdA
- DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ⁇ ybdA::cat can be transferred to the E. coli L-glutamate-producing strain VL334thrC + (EP 1172433) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab.
- strain VL334thrC + has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on December 6, 2004 under the accession number VKPM B-8961 and then converted to a deposit under the Budapest Treaty on December 8, 2004.
- VKPM Russian National Collection of Industrial Microorganisms
- Both strains, VL334thrC + and VL334thrC + - ⁇ ybdA, can be grown for 18-24 hours at 37 0 C on L-agar plates. Then, one loop of the cells can be transferred into test tubes containing 2ml of fermentation medium.
- the fermentation medium contains glucose (6OgA), ammonium sulfate (25 g/1), KH 2 PO 4 (2g/l), MgSO 4 (I g/1), thiamine (0.1 mg/ml), L-isoleucine (70 ⁇ g/ml), and CaCO 3 (25 g/1).
- the pH is adjusted to 7.2.
- Glucose and CaCO 3 are sterilized separately. Cultivation can be carried out at 30°C for 3 days with shaking.
- the amount of L-glutamic acid which is produced can be determined by paper chromatography (liquid phase composition of butanol-acetic acid- water ⁇ : 1:1) with subsequent staining by ninhydrin (1% solution in acetone) and further elution of the compounds in 50% ethanol with 0.5% CdCl 2 .
- Both strains, AJ12739- ⁇ ybdA and AJ12739 can be cultivated at 37°C for 18 hours in a nutrient broth, and 0.3 ml of the obtained culture can each be inoculated into 3 ml of a fermentation medium in a 20x200-mm test tube and cultivated at 37°C for 48 hours with shaking on a rotary shaker. After cultivation, the amount of phenylalanine which accumulates in the medium can be determined by TLC.
- the 10x15 -cm TLC plates coated with 0.11 -mm layers of Sorbfil silica gel containing no fluorescent indicator (Stock Company Sorbpolymer, Krasnodar, Russia) can be used.
- a solution of ninhydrin (2%) in acetone can be used as a visualizing reagent.
- composition of the fermentation medium (g/1) is as follows: Glucose 40.0
- Glucose and magnesium sulfate are sterilized separately.
- CaCO 3 is dry-heat sterilized at 180° for 2 hours. The pH is adjusted to 7.0.
- Example 9 Production of L- tryptophan by E. coli SVl 64 (pGH5V A vbdA
- E. coli SVl 64 pGH5V A vbdA
- DNA fragments from the chromosome of the above-described E. coli strain MG1655 ⁇ ybdA::cat can be transferred to the tryptophan-producing E. coli strain SV164 (pGH5) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain SV164(pGH5)- ⁇ ybdA.
- the strain SV164 has the trpE allele encoding anthranilate synthase free from feedback inhibition by tryptophan.
- the plasmid pGH5 harbors a mutant serA gene encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine.
- the strain SVl 64 (pGH5) was described in detail in US patent No. 6,180,373 or European patent 0662143.
- the obtained cultures (0.3 ml each) can each be inoculated into 3 ml of a fermentation medium containing tetracycline (20 mg/1) in 20 x 200-mm test tubes, and cultivated at 37°C for 48 hours with a rotary shaker at 250 rpm.
- the amount of tryptophan which accumulates in the medium can be determined by TLC as described in Example 8.
- the fermentation medium components are listed in Table 2, but should be sterilized in separate groups (A, B, C, D, E, F, and H), as shown, to avoid adverse interactions during sterilization. Table 2
- Group A had pH 7.1 adjusted by NH 4 OH. Each group is sterilized separately, chilled, and then mixed together.
- Example 10 Production of L-proline by E. coli 702ilvA- ⁇ ybdA
- DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ⁇ ybdA::cat can be transferred to the proline-producing E. coli strain 702ilvA by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain 702ilvA- ⁇ ybdA.
- strain 702ilvA has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on July 18, 2000 under accession number VKPM B-8012 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
- VKPM Russian National Collection of Industrial Microorganisms
- Both E. coli strains, 702ilvA and 702ilvA- ⁇ ybdA can be grown for 18-24 hours at 37°C on L-agar plates. Then, these strains can be cultivated under the same conditions as in Example 8.
- Example 11 Production of L-arginine by E. coli 382- ⁇ vbdA
- DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ⁇ ybdA::cat were transferred to the arginine-producing E. coli strain 382 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain strain 382- ⁇ ybdA.
- the strain 382 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (USD, 117545 Moscow, 1 Dorozhny proezd, 1) on April 10, 2000 under accession number VKPM B-7926 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
- VKPM Russian National Collection of Industrial Microorganisms
- Both strains, 382- ⁇ ybdA and 382 were separately cultivated with shaking at 37°C for 18 hours in 3 ml of nutrient broth, and 0.3 ml of the obtained cultures was inoculated into 2 ml of a fermentation medium in 20 x 200-mm test tubes and cultivated at 32°C for 48 hours on a rotary shaker.
- composition of the fermentation medium (g/1) was as follows:
- Glucose and magnesium sulfate were sterilized separately.
- CaCO 3 was dry-heat sterilized at 180°C for 2 hours. The pH was adjusted to 7.0.
- L-amino acid of a bacterium of the Enterobacteriaceae family can be enhanced.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the ybdA gene.
Description
DESCRIPTION
A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERJACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE ybdA GENE
Technical Field
The present invention relates to the microbiological industry, and specifically to a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family which has been modified to attenuate expression of the ybdA gene.
Background Art
Conventionally, L-amino acids are industrially produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, or mutants thereof. Typically, the microorganisms are modified to enhance production yields of L-amino acids.
Many techniques to enhance L-amino acid production yields have been reported, including transformation of microorganisms with recombinant DNA (see, for example, US patent No. 4,278,765). Other techniques for enhancing production yields include increasing the activities of enzymes involved in amino acid biosynthesis and/or desensitizing the target enzymes of the feedback inhibition by the resulting L-amino acid (see, for example, WO 95/16042 or US patent Nos. 4,346,170; 5,661,012 and 6,040,160).
Another way to enhance L-amino acid production yields is to attenuate expression of a gene or several genes involved in degradation of the target L-amino acid, genes diverting the precursors of the target L-amino acid from the L-amino acid biosynthetic pathway, genes involved in the redistribution of carbon, nitrogen, and phosphate fluxes, and genes coding for toxins etc.
The enterobactin system for iron transport in Escherichia coli is well characterized, with the exception of the mechanism of enterobactin secretion to the extracellular environment. Escherichia coli membrane protein P43(YbdA), encoded by ybdA in the chromosomal region of genes involved in enterobactin synthesis, shows strong homology to the 12-transmembrane segment major facilitator superfamily of export pumps. P43(YbdA) is a critical component of the E. coli enterobactin secretion machinery and the rationale behind its previous designation as entS reflects its biological function (Eis . L. Furrer, et al, MoI. Microbiol, 44(5): 1225-34(2002)).
But currently, there have been no reports of attenuating expression of the ybdA gene for the purpose of producing L-amino acids.
Summary of the Invention
Objects of the present invention include enhancing the productivity of L-amino acid-producing strains and providing a method for producing an L-amino acid using these strains.
The above objects were achieved by finding that attenuating expression of iheybdA gene can enhance production of L-amino acids, such as L-threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L- valine, L-histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, L-arginine, L- phenylalanine, L-tyrosine, and L-tryptophan.
The present invention provides a bacterium of the Enterobacteriaceae family having an increased ability to produce amino acids, such as L-threonine, L-lysine, L- cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, L-arginine, L-phenylalanine, L-tyrosine, and L-tryptophan.
It is an object of the present invention to provide an L-amino acid-producing bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified to attenuate expression of the ybdA gene.
It is a further object of the present invention to provide the bacterium as described above, wherein the expression of the ybdA gene is attenuated by inactivation of the ybdA gene.
It is a further object of the present invention to provide the bacterium as described above, wherein the bacterium belongs to the genus Escherichia.
It is a further object of the present invention to provide the bacterium as described above, wherein the bacterium belongs to the genus Pantoea.
It is a further object of the present invention to provide the bacterium as described above, wherein said L-amino acid is selected from the group consisting of an aromatic L- amino acid and a non-aromatic L-amino acid.
It is a further object of the present invention to provide the bacterium as described above, wherein said aromatic L-amino acid is selected from the group consisting of L- phenylalanine, L-tyrosine, and L-tryptophan.
It is a further object of the present invention to provide the bacterium as described above, wherein said non-aromatic L-amino acid is selected from the group consisting of L- threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-
histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L- glutamic acid, L-proline, and L-arginine.
It is a further object of the present invention to provide a method for producing an L-aniino acid comprising:
- cultivating the bacterium as described above in a medium, and
- collecting said L-amino acid from the medium.
It is a further object of the present invention to provide the method as described above, wherein said L-amino acid is selected from the group consisting of an aromatic L- amino acid and a non-aromatic L-amino acid.
It is a further object of the present invention to provide the method as described above, wherein said aromatic L-amino acid is selected from the group consisting of L- phenylalanine, L-tyrosine, and L-tryptophan.
It is a further object of the present invention to provide the method as described above, wherein said non-aromatic L-amino acid is selected from the group consisting of L- threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L- histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L- glutamic acid, L-proline, and L-arginine.
The present invention is described in detail below.
Detailed Description of the Preferred Embodiments 1. Bacterium of the present invention
The bacterium of the present invention is an L-amino acid-producing bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified to attenuate expression of the ybdA gene.
In the present invention, "L-amino acid-producing bacterium" means a bacterium which has an ability to produce and excrete an L-amino acid into a medium, when the bacterium is cultured in the medium.
The term "L-amino acid-producing bacterium" as used herein also means a bacterium which is able to produce and cause accumulation of an L-amino acid in a culture medium in an amount larger than a wild-type or parental strain of the bacterium, for example, E. coli, such as E. coli K- 12, and preferably means that the bacterium is able to cause accumulation in a medium of an amount not less than 0.5 g/L, more preferably not less than 1.0 g/L, of the target L-amino acid. The term "L-amino acid" includes L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L- proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.
The term "aromatic L-amino acid" includes L-phenylalanine, L-tyrosine, and L- tryptophan. The term "non-aromatic L-amino acid" includes L-threonine, L-lysine, L- cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, and L- arginine. L-threonine, L-lysine, L-cysteine, L-leucine, L-histidine, L-glutamic acid, L- phenylalanine, L-tryptophan, L-proline, and L-arginine are particularly preferred.
The Enterobacteriaceae family includes bacteria belonging to the genera Escherichia, Enter obacter, Erwinia, Klebsiella, Pantoea, Photorhabdus, Providencia, Salmonella, Serratia, Shigella, Morganella, Yersinia, etc. Specifically, those classified into the Enterobacteriaceae according to the taxonomy used by the NCBI (National Center for Biotechnology Information) database
(http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=91347) can be used. A bacterium belonging to the genus Escherichia or Pantoea is preferred.
The phrase "a bacterium belonging to the genus Escherichia" means that the bacterium is classified into the genus Escherichia according to the classification known to a person skilled in the art of microbiology. Examples of a bacterium belonging to the genus Escherichia as used in the present invention include, but are not limited to, Escherichia coli (E. coif).
The bacterium belonging to the genus Escherichia that can be used in the present invention is not particularly limited, however for example, bacteria described by Neidhardt, F.C. et al. (Escherichia coli and Salmonella typhimurium, American Society for Microbiology, Washington D. C, 1208, Table 1) are encompassed by the present invention.
The phrase "a bacterium belonging to the genus Pantoea" means that the bacterium is classified as the genus Pantoea according to the classification known to a person skilled in the art of microbiology. Some species oϊ Enter obacter agglomerans have been recently re-classified into Pantoea agglomerans, Pantoea ananatis, Pantoea stewartii or the like, based on the nucleotide sequence analysis of 16S rRNA, etc. (Int. J. Syst. BacterioL, 43, 162-173 (1993)).
The phrase "bacterium has been modified to attenuate expression of the ybdA gene" means that the bacterium has been modified in such a way that the modified bacterium contains a reduced amount of the YbdA protein as compared with an unmodified bacterium, or the modified bacterium is unable to synthesize the YbdA protein. The phrase "bacterium has been modified to attenuate expression of the ybdA gene" also may mean that the target gene in the bacterium is modified in such a way that the modified gene encodes a mutant YbdA protein which has a decreased activity.
A P43(YbdA)-null mutation was created and siderophore nutrition assays, performed with a panel of E. coli strains expressing one or more outer membrane receptors
for enterobactin-related compounds, demonstrated that the P43(YbdA) mutant was unable to secrete enterobactin efficiently. Products released from the mutant strain were identified with thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC), revealing that the P43 mutant secretes little, if any, enterobactin, but elevated levels of enterobactin breakdown products 2,3- dihydroxybenzoylserine (DHBS) monomer, dimer, and trimer (J. L. Furrer,et.al MoL Microbiol., 44(5): 1225-34(2002)). Therefore, the reduced or absent activity of the YbdA protein in the bacterium according to the present invention can be determined when compared to the parent unmodified bacterium.
The phrase "inactivation of the ybdA gene" means that the modified gene encodes a completely inactive protein. It is also possible that the modified DNA region is unable to naturally express the gene due to the deletion of a part of the gene or of the gene entirely, the shifting of the reading frame of the gene, the introduction of missense/nonsense mutation(s), or the modification of an adjacent region of the gene, including sequences controlling gene expression, such as promoter(s), enhancer(s), attenuator(s), ribosome- binding site(s), etc.
The level of gene expression can be estimated by measuring the amount of mRNA transcribed from the gene using various known methods including Northern blotting, quantitative RT-PCR, and the like. The amount of the protein coded by the gene can be measured by known methods including SDS-PAGE followed by immunoblotting assay (Western blotting analysis) and the like.
The ybdA gene encodes the YbdA protein (synonyms - EntS, B0591). The ybdA gene of E. coli (nucleotides 621,523 to 622,773 in the GenBank accession number NC_000913.2; gi:16128574; SEQ ID NO: 1) is located between the gene fepD and the gene fepB on the chromosome of E. coli strain K-12. The nucleotide sequence of ih&ybdA gene and the amino acid sequence of YbdA encoded by the ybdA gene are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
Since there may be some differences in DNA sequences between the genera or strains of the Enterobacteriaceae family, the ybdA gene to be inactivated on the chromosome is not limited to the gene shown in SEQ ID No:l, but may include genes homologous to SEQ ID No:l encoding a variant protein of the YbdA protein. The phrase "variant protein" as used in the present invention means a protein which has changes in the sequence, whether they are deletions, insertions, additions, or substitutions of amino acids, but still maintains the activity of the product as the YbdA protein. The number of changes in the variant protein depends on the position in the three dimensional structure of the protein or the type of amino acid residues. It may be 1 to 30, preferably 1 to 15, and more preferably 1 to 5 in SEQ ID NO: 2. These changes in the variants are conservative mutations that preserve the function of the protein. In other words, these changes in the
variants can occur in regions of the protein which are not critical for the function of the protein. This is because some amino acids have high homology to one another so the three dimensional structure or activity is not affected by such a change. A conservative mutation is a mutation wherein substitution takes place mutually among Phe, Trp, Tyr, if the substitution site is an aromatic amino acid; among Leu, He, VaI, if the substitution site is a hydrophobic amino acid; between GIn, Asn, if it is a polar amino acid; among Lys, Arg, His, if it is a basic amino acid; between Asp, GIu, if it is an acidic amino acid; and between Ser, Thr, if it is an amino acid having a hydroxyl group. Typical conservative mutations are conservative substitutions. Specific examples of substitutions that are considered to be conservative include: substitution of Ala with Ser or Thr; substitution of Arg with GIn, His, or Lys; substitution of Asn with GIu, GIn, Lys, His, or Asp; substitution of Asp with Asn, GIu, or GIn; substitution of Cys with Ser or Ala; substitution of GIn with Asn, GIu, Lys, His, Asp, or Arg; substitution of GIu with GIy, Asn, GIn, Lys, or Asp; substitution of GIy with Pro; substitution of His with Asn, Lys, GIn, Arg, or Tyr; substitution of He with Leu, Met, VaI, or Phe; substitution of Leu with He, Met, VaI, or Phe; substitution of Lys with Asn, GIu, GIn, His, or Arg; substitution of Met with He, Leu, VaI, or Phe; substitution of Phe with Trp, Tyr, Met, He, or Leu; substitution of Ser with Thr or Ala; substitution of Thr with Ser or Ala; substitution of Trp with Phe or Tyr; substitution of Tyr with His, Phe, or Trp; and substitution of VaI with Met, He, or Leu. Substitutions, deletions, insertions, additions, or inversions and the like of the amino acids described above include naturally occurred mutations (mutant or variant) depending on differences in species, or individual differences of microorganisms that retain the ybdA gene. Such a gene can be obtained by modifying the nucleotide sequence shown in SEQ ID NO: 1 using, for example, site- directed mutagenesis, so that the site-specific amino acid residue in the protein encoded includes substitutions, deletions, insertions, or additions.
Moreover, the protein variant encoded by the ybdA gene may be one which has a homology of not less than 80%, preferably not less than 90%, and most preferably not less than 95%, with respect to the entire amino acid sequence shown in SEQ ID NO. 2, as long as the activity of the YbdA protein prior to inactivation is maintained.
Homology between two amino acid sequences can be determined using the well- known methods, for example, the computer program BLAST 2.0, which calculates three parameters: score, identity and similarity.
Moreover, the ybdA gene may be a variant which hybridizes under stringent conditions with the nucleotide sequence shown in SEQ ID NO: 1, or a probe which can be prepared from the nucleotide sequence under stringent conditions, provided that it encodes a functional YbdA protein prior to inactivation. "Stringent conditions" include those under which a specific hybrid, for example, a hybrid having homology of not less than 60%,
preferably not less than 70%, more preferably not less than 80%, still more preferably not less than 90%, and most preferably not less than 95%, is formed and a non-specific hybrid, for example, a hybrid having homology lower than the above, is not formed. For example, stringent conditions are exemplified by washing one time or more, preferably two or three times at a salt concentration of 1 xSSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS at 6O0C. Duration of washing depends on the type of membrane used for blotting and, as a rule, should be what is recommended by the manufacturer. For example, the recommended duration of washing for the Hybond™ N+ nylon membrane (Amersham) under stringent conditions is 15 minutes. Preferably, washing may be performed 2 to 3 times. The length of the probe may be suitably selected, depending on the hybridization conditions, in this specific case, it may be about 100 bp to 1 kbp.
Expression of the ybdA gene can be attenuated by introducing a mutation into the gene on the chromosome so that the intracellular activity of protein encoded by the gene is decreased as compared with an unmodified strain. Such a mutation on the gene can be replacement of one base or more to cause amino acid substitution in the protein encoded by the gene (missense mutation), introduction of a stop codon (nonsense mutation), deletion of one or two bases to cause a frame shift, insertion of a drug-resistance gene, or deletion of a part of the gene or the entire gene (Qiu, Z. and Goodman, M.F., J. Biol. Chem., 272, 8611-8617 (1997); Kwon, D. H. et al, J. Antimicrob. Chemother., 46, 793-796 (2000)). Expression of the ybdA gene can also be attenuated by modifying an expression regulating sequence such as the promoter, the Shine-Dalgarno (SD) sequence, etc. (WO95/34672, Carrier, T.A. and Keasling, J.D., Biotechnol Prog 15, 58-64 (1999)).
For example, the following methods may be employed to introduce a mutation by gene recombination. A mutant gene encoding a mutant protein having a decreased activity is prepared, and a bacterium to be modified is transformed with a DNA fragment containing the mutant gene. Then, the native gene on the chromosome is replaced with the mutant gene by homologous recombination, and the resulting strain is selected. Such gene replacement by homologous recombination can be conducted by employing a linear DNA, which is known as "Red-driven integration" (Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 97, 12, p 6640-6645 (2000), WO2005/010175), or by methods employing a plasmid containing a temperature-sensitive replication control region (Proc. Natl. Acad. Sci., USA, 97, 12, p 6640-6645 (2000), U.S. Patent Nos. 6,303,383 and 5,616,480). Furthermore, the introduction of a site-specific mutation by gene replacement using homologous recombination as set forth above can also be performed by using a plasmid lacking the ability to replicate in the host.
Expression of the gene can also be attenuated by insertion of a transposon or an IS factor into the coding region of the gene (U.S. Patent No. 5,175,107), or by conventional
methods, such as mutagenesis with UV irradiation or nitrosoguanidine (N-methyl-N'-nitro- N-nitrosoguanidine) .
Inactivation of the gene can also be performed by conventional methods, such as by mutagenesis using UV irradiation or nitrosoguanidine (N-methyl-N'-nitro-N- nitrosoguanidine), site-directed mutagenesis, gene disruption using homologous recombination, or/and insertion-deletion mutagenesis (Yu, D. et al., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 5978-83 and Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 6640-45) also called "Red-driven integration".
The presence or absence of the ybdA gene on the chromosome of a bacterium can be detected by well-known methods, including PCR, Southern blotting, and the like, hi addition, the level of gene expression can be estimated by measuring the amount of mRNA transcribed from the gene using various well-known methods, including Northern blotting, quantitative RT-PCR, and the like. The amount or molecular weight of the protein encoded by the gene can be measured by well-known methods, including SDS-PAGE followed by immunoblotting assay (Western blotting analysis), and the like.
Methods for preparation of plasmid DNA, digestion and ligation of DNA, transformation, selection of an oligonucleotide as a primer, and the like may be ordinary methods well-known to one skilled in the art. These methods are described, for instance, in Sambrook, J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning: A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989).
L-amino acid-producing bacteria
As a bacterium of the present invention which is modified to attenuate expression of the ybdA gene, bacteria which are able to produce either an aromatic or a non-aromatic L-amino acids may be used.
The bacterium of the present invention can be obtained by attenuating expression of the ybdA gene in a bacterium which inherently has the ability to produce an L-amino acid. Alternatively, the bacterium of present invention can be obtained by imparting the ability to produce L-amino acids to a bacterium already having the attenuated expression of the ybdA gene.
L-threonine-producing bacteria
Examples of parent strains for deriving the L-threonine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli TDH-6/pVIC40 (VKPM B-3996) (U.S. Patent No. 5, 175, 107, U.S. Patent No. 5,705,371), E. coli 472T23/pYN7 (ATCC 98081) (U.S. Patent No.5,631,157), E. coli NRRL-21593 (U.S. Patent No. 5,939,307), E. coli FERM BP-3756 (U.S. Patent No.
5,474,918), E. coli FERM BP-3519 and FERM BP-3520 (U.S. Patent No. 5,376,538), E. coli MG442 (Gusyatiner et al., Genetika (in Russian), 14, 947-956 (1978)), E. coli VL643 and VL2055 (EP 1149911 A), and the like.
The strain TDH-6 is deficient in the thrC gene, as well as being sucrose- assimilative, and the HvA gene has a leaky mutation. This strain also has a mutation in the rhtA gene, which imparts resistance to high concentrations of threonine or homoserine. The strain B-3996 contains the plasmid pVIC40 which was obtained by inserting a thrA*BC operon which includes a mutant thrA gene into a RSFlOlO-derived vector. This mutant thrA gene encodes aspartokinase homoserine dehydrogenase I which has substantially desensitized feedback inhibition by threonine. The strain B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (Russia, 117105 Moscow, Nagatinskaya Street, 3 -A) under the accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow 1, Dorozhny proezd. 1) on April 7, 1987 under the accession number VKPM B-3996.
E. coli VKPM B-5318 (EP 0593792B) may also be used as a parent strain for deriving L-threonine-producing bacteria of the present invention. The strain B-5318 is prototrophic with regard to isoleucine, and a temperature-sensitive lambda-phage Cl repressor and PR promoter replaces the regulatory region of the threonine operon in plasmid pVIC40. The strain VKPM B-5318 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM) on May 3, 1990 under accession number of VKPM B-5318.
Preferably, the bacterium of the present invention is additionally modified to enhance expression of one or more of the following genes: the mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine; the thrB gene which codes for homoserine kinase; the thrC gene which codes for threonine synthase; the rhtA gene which codes for a putative transmembrane protein; the asd gene which codes for aspartate-β-semialdehyde dehydrogenase; and the aspC gene which codes for aspartate aminotransferase (aspartate transaminase);
The thrA gene which encodes aspartokinase homoserine dehydrogenase I of Escherichia coli has been elucidated (nucleotide positions 337 to 2799, GenBank accession no.NC_000913.2, gi: 49175990). The thrA gene is located between the thrL and thrB genes on the chromosome of E. coli K-12. The thrB gene which encodes homoserine kinase of Escherichia coli has been elucidated (nucleotide positions 2801 to 3733, GenBank
accession no.NC_000913.2, gi: 49175990). The thrB gene is located between the thrA and thrC genes on the chromosome of E. coli K- 12. The thrC gene which encodes threonine synthase of Escherichia coli has been elucidated (nucleotide positions 3734 to 5020, GenBank accession no.NC_000913.2, gi: 49175990). The thrC gene is located between the thrB gene and the yaa∑ open reading frame on the chromosome of E. coli K- 12. All three genes function as a single threonine operon. To enhance expression of the threonine operon, the attenuator region which affects the transcription is removed from the operon (WO2005/049808, WO2003/097839).
A mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine, as well as the thrB and thrC genes can be obtained as one operon from the well-known plasmid pVIC40 which is present in the threonine producing E. coli strain VKPM B-3996. Plasmid pVIC40 is described in detail in U.S. Patent No. 5,705,371.
The rhtA gene exists at 18 min on the E. coli chromosome close to the glnHPQ operon, which encodes components of the glutamine transport system. The rhtA gene is identical to ORFl (ybiF gene, nucleotide positions 764 to 1651, GenBank accession number AAA218541, gi:440181) and is located between the pexB and ompX genes. The unit expressing a protein encoded by the ORFl has been designated the rhtA gene (rht: resistance to homoserine and threonine). Also, it was revealed that the rhtA23 mutation is an A-for-G substitution at position -1 with respect to the ATG start codon (ABSTRACTS of the 17* International Congress of Biochemistry and Molecular Biology in conjugation with the Annual Meeting of the American Society for Biochemistry and Molecular Biology, San Francisco, California August 24-29, 1997, abstract No. 457, EP 1013765 A).
The asd gene of E. coli has already been elucidated (nucleotide positions 3572511 to 3571408, GenBank accession no. NC_000913.1, gi:16131307), and can be obtained by PCR (polymerase chain reaction; refer to White, TJ. et al, Trends Genet., 5, 185 (1989)) utilizing primers prepared based on the nucleotide sequence of the gene. The asd genes of other microorganisms can be obtained in a similar manner.
Also, the aspC gene of E. coli has already been elucidated (nucleotide positions 983742 to 984932, GenBank accession no. NC_000913.1, gi: 16128895), and can be obtained by PCR. The aspC genes of other microorganisms can be obtained in a similar manner.
L-lysine-producing bacteria
Examples of L-lysine-producing bacteria belonging to the genus Escherichia include mutants having resistance to an L-lysine analogue. The L-lysine analogue inhibits growth of bacteria belonging to the genus Escherichia, but this inhibition is fully or
partially desensitized when L-Iy sine coexists in a medium. Examples of the L-lysine analogue include, but are not limited to, oxalysine, lysine hydroxamate, S-(2-aminoethyl)- L-cysteine (AEC), γ-methyllysine, α-chlorocaprolactam, and so forth. Mutants having resistance to these lysine analogues can be obtained by subjecting bacteria belonging to the genus Escherichia to a conventional artificial mutagenesis treatment. Specific examples of bacterial strains useful for producing L-lysine include Escherichia coli AJl 1442 (FERM BP-1543, NRRL B-12185; see U.S. Patent No. 4,346,170) and Escherichia coli VL611. In these microorganisms, feedback inhibition of aspartokinase by L-lysine is desensitized.
The strain WC 196 may be used as an L-lysine producing bacterium of Escherichia coli. This bacterial strain was bred by conferring AEC resistance to the strain W3110, which was derived from Escherichia coli K- 12. The resulting strain was designated Escherichia coli AJl 3069 and was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on December 6, 1994 and received an accession number of FERM P- 14690. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and received an accession number of FERM BP-5252 (U.S. Patent No. 5,827,698).
Examples of parent strains for deriving L-lysine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- lysine biosynthetic enzyme are enhanced. Examples of such genes include, but are not limited to, genes encoding dihydrodipicolinate synthase (dapA), aspartokinase (lysC), dihydrodipicolinate reductase (dapB), diaminopimelate decarboxylase (lysA), diaminopimelate dehydrogenase (ddh) (U.S. Patent No. 6,040,160), phosphoenolpyrvate carboxylase (ppc), aspartate semialdehyde dehydrogenease (asd), and aspartase (aspA) (EP 1253195 A). In addition, the parent strains may have increased expression of the gene involved in energy efficiency (cyo) (EP 1170376 A), the gene encoding nicotinamide nucleotide transhydrogenase (pntAB) (U.S. Patent No. 5,830,716), iheybjE gene (WO2005/073390), or combinations thereof.
Examples of parent strains for deriving L-lysine-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine. Examples of the enzymes that catalyze a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine include homoserine dehydrogenase, lysine decarboxylase (U.S. Patent No. 5,827,698), and the malic enzyme (WO2005/010175).
L-cvsteine-producing bacteria
Examples of parent strains for deriving L-cysteine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli JMl 5 which is transformed with different cysE alleles coding for feedback- resistant serine acetyltransferases (U.S. Patent No. 6,218,168, Russian patent application 2003121601); E. coli W3110 having over-expressed genes which encode proteins suitable for secreting substances toxic for cells (U.S. Patent No. 5,972,663); E. coli strains having lowered cysteine desulfohydrase activity (JPl 1155571 A2); E. coli W3110 with increased activity of a positive transcriptional regulator for cysteine regulon encoded by the cysB gene (WO0127307A1), and the like.
L-leucine-producing bacteria
Examples of parent strains for deriving L-leucine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strains resistant to leucine (for example, the strain 57 (VKPM B-7386, U.S. Patent No. 6,124,121)) or leucine analogs including β-2-thienylalanine, 3-hydroxyleucine, 4-azaleucine, 5,5,5-trifluoroleucine (JP 62-34397 B and JP 8-70879 A); E. coli strains obtained by the gene engineering method described in WO96/06926; E. coli H-9068 (JP 8- 70879 A), and the like.
The bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-leucine biosynthesis. Examples include genes of the leuABCD operon, which are preferably represented by a mutant leuA gene coding for isopropylmalate synthase which is freed from feedback inhibition by L-leucine (US Patent No. 6,403,342). In addition, the bacterium of the present invention may be improved by enhancing the expression of one or more genes coding for proteins which excrete L-amino acid from the bacterial cell. Examples of such genes include the b2682 and b2683 genes (ygaZH genes) (EP 1239041 A2).
L-histidine-producing bacteria
Examples of parent strains for deriving L-histidine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strain 24 (VKPM B-5945, RU2003677); E. coli strain 80 (VKPM B-7270, RU2119536); E. coli NRRL B-12116 - B12121 (U.S. Patent No. 4,388,405); E. coli H- 9342 (FERM BP-6675) and H-9343 (FERM BP-6676) (U.S. Patent No. 6,344,347); E. coli H-9341 (FERM BP-6674) (EP 1085087); E. coli AI80/pFM201 (U,S. Patent No. 6,258,554) and the like.
Examples of parent strains for deriving L-histidine-producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L-histidine biosynthetic enzyme are enhanced. Examples of such genes include genes encoding ATP phosphoribosyltransferase (hisG), phosphoribosyl AMP cyclohydrolase (hisl), phosphoribosyl-ATP pyrophosphohydrolase (hisIE), phosphoribosylformimino-5- arninoimidazole carboxamide ribotide isomerase (hisA), amidotransferase (hisH), histidinol phosphate aminotransferase (hisC), histidinol phosphatase (hisB), histidinol dehydrogenase (hisD), and so forth.
It is known that the L-histidine biosynthetic enzymes encoded by MsG and hisBHAFI are inhibited by L-histidine, and therefore an L-histidine-producing ability can also be efficiently enhanced by introducing a mutation into ATP phosphoribosyltransferase which imparts resistance to the feedback inhibition (Russian Patent Nos. 2003677 and 2119536).
Specific examples of strains having an L-histidine-producing ability include E. coli FERM P-5038 and 5048 which have been introduced with a vector carrying a DNA encoding an L-histidine-biosynthetic enzyme (JP 56-005099 A), E. coli strains introduced with rht, a gene for an amino acid-export (EPl 016710A), E. coli 80 strain imparted with sulfaguanidine, DL- 1 ,2,4-triazole-3 -alanine, and streptomycin-resistance (VKPM B-7270, Russian Patent No. 2119536), and so forth.
L-glutamic acid-producing bacteria
Examples of parent strains for deriving L-glutamic acid-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli VL334thrC+ (EP 1172433). E. coli VL334 (VKPM B-1641) is an L- isoleucine and L-threonine auxotrophic strain having mutations in thrC and UvA genes (U.S. Patent No. 4,278,765). A wild-type allele of the thrC gene was transferred by the method of general transduction using a bacteriophage Pl which was grown on wild-type E. coli K12 (VKPM B-7) cells. As a result, an L-isoleucine auxotrophic strain VL334thrC+ (VKPM B-8961), which is able to produce L-glutamic acid, was obtained.
Examples of parent strains for deriving the L-glutamic acid-producing bacteria of the present invention include, but are not limited to, strains which are deficient in α- ketoglutarate dehydrogenase activity, or strains in which one or more genes encoding an L- glutamic acid biosynthetic enzyme are enhanced. Examples of the genes involved in L- glutamic acid biosynthesis include genes encoding glutamate dehydrogenase (gdhA), glutamine synthetase (glnA), glutamate synthetase (gltAB), isocitrate dehydrogenase (icdA), aconitate hydratase {acnA, acnB), citrate synthase (gltA), phosphoenolpyruvate carboxylase (ppc), pyruvate carboxylase (pyc), pyruvate dehydrogenase (aceEF, ipdA),
pyruvate kinase (pykA,pykF), phosphoenolpyruvate synthase (ppsA), enolase (eno), phosphoglyceromutase (pgmA, pgml), phosphoglycerate kinase (pgk), glyceraldehyde-3- phophate dehydrogenase (gapA), triose phosphate isomerase (tpiA), fructose bisphosphate aldolase (fl>p), phosphofructokinase (pflcA, pflcB), and glucose phosphate isomerase (pgi).
Examples of strains modified so that expression of the citrate synthetase gene, the phosphoenolpyruvate carboxylase gene, and/or the glutamate dehydrogenase gene is/are enhanced include those disclosed in EP1078989A, EP955368A, and EP952221A.
Examples of strains which have been modified so that expression of the citrate synthetase gene and/or the phosphoenolpyruvate carboxylase gene are reduced, and/or/are deficient in α-ketoglutarate dehydrogenase activity include those disclosed in EP1078989A, EP955368A, and EP952221A.
Examples of parent strains for deriving the L-glutamic acid-producing bacteria of the present invention also include strains having decreased or eliminated activity of an enzyme that catalyzes synthesis of a compound other than L-glutamic acid by branching off from an L-glutamic acid biosynthesis pathway. Examples of such enzymes include isocitrate lyase (aceA), α-ketoglutarate dehydrogenase (sucA), phosphotransacetylase (ptά), acetate kinase (ack), acetohydroxy acid synthase (UvG), acetolactate synthase (UvI), formate acetyltransferase (pfl), lactate dehydrogenase (Idh), and glutamate decarboxylase (gadAB). Bacteria belonging to the genus Escherichia deficient in α-ketoglutarate dehydrogenase activity or having a reduced reduced α-ketoglutarate dehydrogenase activity and methods for obtaining them are described in U.S. Patent Nos. 5,378,616 and 5,573,945. Specifically, these strains include the following:
E. co/z W311 OsucA::Kmr
E. coli AJ12624 (FERM BP-3853)
E. coli AJ12628 (FERM BP-3854)
E. coli AJ12949 (FERM BP-4881)
E. coli W3110sucA::Kmr is a strain obtained by disrupting the α-ketoglutarate dehydrogenase gene (hereinafter referred to as "sucA gene") of E. coli W3110. This strain is completely deficient in α-ketoglutarate dehydrogenase.
Other examples of L-glutamic acid-producing bacteria include those which belong to the genus Escherichia and have resistance to an aspartic acid antimetabolite. These strains can also be deficient in α-ketoglutarate dehydrogenase activity and include, for example, E. coli AJ13199 (FERM BP-5807) (U.S. Patent No. 5.908,768), FFRM P-12379, which additionally has a low L-glutamic acid decomposing ability (U.S. Patent No. 5,393,671); AJ13138 (FERM BP-5565) (U.S. Patent No. 6,110,714), and the like.
Examples of L-glutamic acid-producing bacteria, include mutant strains belonging to the genus Pantoea which are deficient in α-ketoglutarate dehydrogenase activity or have
decreased α-ketoglutarate dehydrogenase activity, and can be obtained as described above. Such strains include Pantoea ananatis AJ13356. (U.S. Patent No. 6,331,419). Pantoea ananatis AJ13356 was deposited at the National Institute of Bioscience and Human- Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on February 19, 1998 under an accession number of FERM P- 16645. It was then converted to an international deposit under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP- 6615. Pantoea ananatis AJ13356 is deficient in α-ketoglutarate dehydrogenase activity as a result of disruption of the αKGDH-El subunit gene (sucA). The above strain was identified as Enterobacter agglomerans when it was isolated and deposited as Enterobacter agglomerans AJl 3356. However, it was recently re-classified as Pantoea ananatis on the basis of nucleotide sequencing of 16S rRNA and so forth. Although AJ13356 was deposited at the aforementioned depository as Enterobacter agglomerans, for the purposes of this specification, they are described as Pantoea ananatis.
L-phenylalanine-producing bacteria
Examples of parent strains for deriving L-phenylalanine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli AJ12739 (tyrA::TnlO, tyrR) (VKPM B-8197); E. coli HW1089 (ATCC 55371) harboring the mutant pheA34 gene (U.S. Patent No. 5,354,672); E. coli MWEC101-b (KR8903681); E. coli NPvRL B-12141, NRRL B-12145, NRRL B-12146 and NRRL B-12147 (U.S. Patent No. 4,407,952). Also, as a parent strain, E. coli K-12 [W3110 (tyrA)/pPHAB (FERM BP-3566), E. coli K-12 [W3110 (tyrA)/pPHAD] (FERM BP- 12659), E. coli K-12 [W3110 (tyrA)/pPHATerm] (FERM BP-12662) and E. coli K-12 [W3110 (tyrA)/pBR-aroG4, pACMAB] named as AJ 12604 (FERM BP-3579) may be used (EP 488424 Bl). Furthermore, L-phenylalanine producing bacteria belonging to the genus Escherichia with an enhanced activity of the protein encoded by the yedA gene or the yddG gene may also be used (U.S. patent applications 2003/0148473 Al and 2003/0157667 Al).
L-tryptophan-producing bacteria
Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli JP4735/pMU3028 (DSM10122) and JP6015/pMU91 (DSM10123) which is deficient in the tryptophanyl-tRNA synthetase encoded by mutant trpS gene (U.S. Patent
No. 5,756,345); E. coli SVl 64 (pGH5) having a serA allele encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine and a trpE allele encoding anthranilate synthase free from feedback inhibition by tryptophan (U.S. Patent No. 6,180,373); E. coli AGX17 (pGX44) (NRRL B-12263) and AGX6(pGX50)aroP (NRRL B-12264) deficient in the enzyme tryptophanase (U.S. Patent No. 4,371,614); E. coli AGX17/pGX50,pACKG4-pps in which a phosphoenolpyruvate-producing ability is enhanced (WO9708333, U.S. Patent No. 6,319,696), and the like may be used. L- tryptophan-producing bacteria belonging to the genus Escherichia with an enhanced activity of the identified protein encoded by and the yedA gene or the yddG gene may also be used (U.S. patent applications 2003/0148473 Al and 2003/0157667 Al).
Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains in which one or more activities of the enzymes selected from anthranilate synthase, phosphoglycerate dehydrogenase, and tryptophan synthase are enhanced. The anthranilate synthase and phosphoglycerate dehydrogenase are both subject to feedback inhibition by L-tryptophan and L-serine, so that a mutation desensitizing the feedback inhibition may be introduced into these enzymes. Specific examples of strains having such a mutation include a E. coli SVl 64 which harbors desensitized anthranilate synthase and a transformant strain obtained by introducing into the E. coli SV164 the plasmid ρGH5 (WO 94/08031), which contains a mutant serA gene encoding feedback-desensitized phosphoglycerate dehydrogenase.
Examples of parent strains for deriving the L-tryptophan-producing bacteria of the present invention also include strains into which the tryptophan operon which contains a gene encoding desensitized anthranilate synthase has been introduced (JP 57-71397 A, JP 62-244382 A, U.S. Patent No. 4,371,614). Moreover, L-tryptophan-producing ability may be imparted by enhancing expression of a gene which encodes tryptophan synthase. The tryptophan synthase consists of α and β subunits which are encoded by the trpA and trpB genes, respectively. In addition, L-tryptophan-producing ability may be improved by enhancing expression of the isocitrate lyase-malate synthase operon (WO2005/103275).
L-proline-producing bacteria
Examples of parent strains for deriving L-proline-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli 702ilvA (VKPM B-8012) which is deficient in the HvA gene and is able to produce L-proline (EP 1172433). The bacterium of the present invention may be improved by enhancing the expression of one or more genes involved in L-proline biosynthesis. Examples of such genes for L-proline producing bacteria include the proB gene coding for glutamate kinasewhich has feedback inhibition by L-proline desensitized (DE Patent
3127361). In addition, the bacterium of the present invention may be improved by enhancing the expression of one or more genes coding for proteins excreting L-amino acid from bacterial cell. Such genes are exemplified by the b2682 and b2683 genes (ygaZH genes) (EP 1239041 A2).
Examples of bacteria belonging to the genus Escherichia, which have an activity to produce L-proline include the following E. coli strains: NRRL B-12403 and NRRL B- 12404 (GB Patent 2075056), VKPM B-8012 (Russian patent application 2000124295), plasmid mutants described in DE Patent 3127361, plasmid mutants described by Bloom F.R. et al (The 15th Miami winter symposium, 1983, p.34), and the like.
L-arginine-producing bacteria
Examples of parent strains for deriving L-arginine-producing bacteria of the present invention include, but are not limited to, strains belonging to the genus Escherichia, such as E. coli strain 237 (VKPM B-7925) (U.S. Patent Application 2002/058315 Al) and its derivative strains harboring mutant N-acetylglutamate synthase (Russian Patent Application No. 2001112869), E. coli strain 382 (VKPM B-7926) (EPl 170358A1), an arginine-producing strain into which argA gene encoding N-acetylglutamate synthetase is introduced therein (EPl 170361 Al), and the like.
Examples of parent strains for deriving L-arginine producing bacteria of the present invention also include strains in which expression of one or more genes encoding an L- arginine biosynthetic enzyme are enhanced. Examples of such genes include genes encoding N-acetylglutamyl phosphate reductase (argC), ornithine acetyl transferase (argJ), N-acetylglutamate kinase (argB), acetyloπiithine transaminase (argD), ornithine carbamoyl transferase (argF), argininosuccinic acid synthetase (argG), argininosuccinic acid lyase (argH), and carbamoyl phosphate synthetase {car AB).
L-valine-producing bacteria
Example of parent strains for deriving L-valine-producing bacteria of the present invention include, but are not limited to, strains which have been modified to overexpress the UvGMEDA operon (U.S. Patent No. 5,998,178). It is desirable to remove the region of the HvGMEDA operon which is required for attenuation so that expression of the operon is not attenuated by the L-valine that is produced. Furthermore, the UvA gene in the operon is desirably disrupted so that threonine deaminase activity is decreased.
Examples of parent strains for deriving L-valine-producing bacteria of the present invention include also include mutants having a mutation of amino-acyl t-RNA synthetase (U.S. Patent No. 5,658,766). For example, E. coli VL1970, which has a mutation in the UeS gene encoding isoleucine iRNA synthetase, can be used. E. coli VL 1970 has been
deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny Proezd, 1) on June 24, 1988 under accession number VKPM B-4411.
Furthermore, mutants requiring lipoic acid for growth and/or lacking H+-ATPaSe can also be used as parent strains (WO96/06926).
L-isoleucine-producing bacteria
Examples of parent strains for deriving L-isoleucine producing bacteria of the present invention include, but are not limited to, mutants having resistance to 6- dimethylaminopurine (JP 5-304969 A), mutants having resistance to an isoleucine analogue such as thiaisoleucine and isoleucine hydroxamate, and mutants additionally having resistance to DL-ethionine and/or arginine hydroxamate (JP 5-130882 A). In addition, recombinant strains transformed with genes encoding proteins involved in L- isoleucine biosynthesis, such as threonine deaminase and acetohydroxate synthase, can also be used as parent strains (JP 2-458 A, FR 0356739, and U.S. Patent No. 5,998,178).
2. Method of the present invention
The method of the present invention is a method for producing an L-amino acid comprising cultivating the bacterium of the present invention in a culture medium to produce and excrete the L-amino acid into the medium, and collecting the L-amino acid from the medium.
In the present invention, the cultivation, collection, and purification of an L-amino acid from the medium and the like may be performed in a manner similar to conventional fermentation methods wherein an amino acid is produced using a bacterium.
The chosen culture medium may be either a synthetic or natural medium, so long as it includes a carbon source and a nitrogen source and minerals and, if necessary, appropriate amounts of nutrients which the bacterium requires for growth. The carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the mode of assimilation of the chosen microorganism, alcohol, including ethanol and glycerol, may be used. As the nitrogen source, various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, and digested fermentative microorganisms can be used. As minerals, potassium monophosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium chloride, and the like can be used. As vitamins, thiamine, yeast extract, and the like, can be used.
The cultivation is preferably performed under aerobic conditions, such as by shaking and/or stirring with aeration, at a temperature of 20 to 40 °C, preferably 30 to
38 °C. The pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2. The pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 5-day cultivation leads to accumulation of the target L-amino acid in the liquid medium.
After cultivation, solids such as cells can be removed from the liquid medium by centrifugation or membrane filtration, and then the L-amino acid can be collected and purified by ion-exchange, concentration, and/or crystallization methods.
Brief Description of Drawings
Figure 1 shows the relative positions of primers ybdAL and ybdAR on plasmid pACYC184, which is used for amplification of the cat gene.
Figure 2 shows the construction of the chromosomal DNA fragment comprising the inactivated yδ^ gene.
Examples
The present invention will be more concretely explained below with reference to the following non-limiting Examples.
Example 1. Construction of a strain with an inactivated ybdA gene.
1. Deletion of the ybdA gene.
The ybdA gene was deleted by the method initially developed by Datsenko, K. A. and Wanner, B.L. (Proc. Natl. Acad. Sci. USA, 2000, 97(12), 6640-6645) called "Red- driven integration". According to this procedure, the PCR primers ybdAL (SEQ ID NO: 3) and ybdAR (SEQ ID NO: 4), which are complementary to both the region adjacent to the ybdA gene and the gene conferring antibiotic resistance, respectively, in the template plasmid, were constructed. The plasmid pACYC184 (NBL Gene Sciences Ltd., UK) (GenBank/EMBL accession number X06403) was used as a template in the PCR reaction. Conditions for PCR were as follows: denaturation step:3 min at 95 0C; profile for two first cycles: 1 min at 95 °C, 30 sec at 50 °C, 40 sec at 72 °C; profile for the last 25 cycles: 30 sec at 95 0C, 30 sec at 54 °C, 40 sec at 72 0C; final step: 5 min at 72 0C.
An 1152 bp PCR product (Fig. 1) was obtained and purified in agarose gel and used for electroporation of E. coli MG 1655 (ATCC 700926), which contains the plasmid pKD46 having a temperature-sensitive replication. The plasmid pKD46 (Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12:6640-45) includes a 2,154 nucleotide (31088-33241) DNA fragment of phage λ (GenBank accession No. J02459), and contains genes of the λ Red homologous recombination system (γ, β, exo genes) under the control of the arabinose-inducible ParaB promoter. The plasmid pKD46 is necessary for
integration of the PCR product into the chromosome of strain MGl 655. The strain MG1655 can be obtained from American Type Culture Collection. (P.O. Box 1549 Manassas, VA 20108, U.S.A.).
Electrocompetent cells were prepared as follows: E. coli MG1655/pKD46 was grown overnight at 30 °C in LB medium containing ampicillin (100 mg/1), and the culture was diluted 100 times with 5 ml of SOB medium (Sambrook et al, "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989)) containing ampicillin and L-arabinose (1 mM). The cells were grown with aeration at 30 °C to an OD600 of «0.6 and then were made electrocompetent by concentrating 100-fold and washing three times with ice-cold deionized H2O. Electroporation was performed using 70 μl of cells and «100 ng of PCR product. Cells after electroporation were incubated with 1 ml of SOC medium (Sambrook et al, "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989)) at 37 0C for 2.5 hours and were then plated onto L-agar containing chloramphenicol (30 μg/ml) and grown at 37 °C to select CmR recombinants. Then, to eliminate the pKD46 plasmid, 2 passages on L-agar with Cm at 42 0C were performed and the obtained colonies were tested for sensitivity to ampicillin.
2. Verification of the ybdA gene deletion by PCR.
The mutants, which have the ybdA gene deleted and are marked with the Cm resistance gene, were verified by PCR. Locus-specific primers ybdAl (SEQ ID NO: 5) and ybdA2 (SEQ ID NO: 6) were used in PCR for verification. Conditions for PCR verification were as follows: denaturation step: 3 min at 94 °C; profile for the 30 cycles: 30 sec at 94 0C, 30 sec at 54 0C, 1 min at 72 °C; final step: 7 min at 72 0C. The PCR product obtained using the parental ybdA+ strain MGl 655 as the template is 1420 bp in length. The PCR product obtained using the mutant strain as the template is 1249 nucleotides in length (Fig.2). The mutant strain was named MGl 655 ΔybdA::cat.
Example 2. Production of L-threonine by E. coli strain B-3996-ΔybdA To test the effect of inactivation of the ybdA gene on threonine production, DNA fragments from the chromosome of the above-described E. coli MGl 655 ΔybdA::cat were transferred to the threonine-producing E. coli strain VKPM B-3996 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain B-3996-ΔybdA. The strain B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (Russia, 117105 Moscow, Nagatinskaya Street 3 -A) under the accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM)
(Russia, 117545 Moscow, 1 Dorozhny proezd, 1) under the accession number VKPM B- 3996.
Both E. coli B-3996 and B-3996-ΔybdA, were grown for 18-24 hours at 370C on L- agar plates. To obtain a seed culture, the strains were grown on a rotary shaker (250 rpm) at 32°C for 18 hours in 20x200-mm test tubes containing 2 ml of L-broth supplemented with 4% glucose. Then, the fermentation medium was inoculated with 0.21 ml (10%) of seed material. The fermentation was performed in 2 ml of minimal medium for fermentation in 20x200-mm test tubes. Cells were grown for 65 hours at 32°C with shaking at 250 rpm.
After cultivation, the amount of L-threonine, which had accumulated in the medium, was determined by paper chromatography using the following mobile phase: butanol : acetic acid : water = 4 : 1 : 1 (v/v). A solution 2% of ninhydrin in acetone was used as a visualizing reagent. A spot containing L-threonine was cut out, L-threonine was eluted in 0.5 % water solution Of CdCl2, and the amount of L-threonine was estimated spectrophotometrically at 540 nm. The results of 5 independent test tube fermentations are shown in Table 1. As follows from Table 1, B-3996-ΔybdA caused accumulation of a higher amount of L-threonine, as compared with B-3996.
The composition of the fermentation medium (g/1) was as follows:
Glucose 80.0
(NEU)2SO4 22.0
NaCl 0.8
KH2PO4 2.0
MgSO4-7H2O 0.8
FeSO4-7H2O 0.02
MnSO4-5H2O 0.02
Thiamine HCl 0.0002
Yeast extract 1.0
CaCO3 30.0
Glucose and magnesium sulfate were sterilized separately. CaCO3 was sterilized by dry-heat at 180°C for 2 hours. The pH was adjusted to 7.0. The antibiotic was introduced into the medium after sterilization.
Table 1
Example 3. Production of L-lvsine by E. coli AJ11442-ΔybdA To test the effect of inactivation of the ybdA gene on lysine production, DNA fragments from the chromosome of the above-described E. coli strain MG1655 ΔybdA::cat can be transferred to the Iy sine-producing E. coli strain AJl 1442 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain AJl 1442-ΔybdA strain. The strain AJ14442 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on May 1, 1981 and received an accession number of FERM P-5084. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on Octobe 29, 1987, and received an accession number of FERM BP- 1543.
Both E. coli strains, AJl 1442 and AJl 1442-ΔybdA, can be cultured in L-medium containing streptomycin (20 mg/1) at 370C, and 0.3 ml of the obtained culture can be inoculated into 20 ml of the fermentation medium containing the required drugs in a 500- ml flask. The cultivation can be carried out at 37°C for 16 h by using a reciprocal shaker at the agitation speed of 115 rpm. After the cultivation, the amounts of L-lysine and residual glucose in the medium can be measured by a known method (Biotech-analyzer AS210 manufactured by Sakura Seiki Co.). Then, the yield of L-lysine can be calculated relative to consumed glucose for each of the strains.
The composition of the fermentation medium (g/1) is as follows:
Glucose 40
(NHt)2SO4 24
K2HPO4 1.0
MgSO4-7H2O 1.0
FeSO4-7H2O 0.01
MnSO4-5H2O 0.01
Yeast extract 2.0
The pH is adjusted to 7.0 by KOH and the medium is autoclaved at 115°C for 10 min. Glucose and MgSO4 7H2O are sterilized separately. CaCO3 is dry-heat sterilized at 180°C for 2 hours and added to the medium for a final concentration of 30 g/1.
Example 4. Production of L-cysteine by E. coli JM15(ydeD>ΔybdA To test the effect of inactivation of theybdA gene on L-cysteine production, DNA fragments from the chromosome of the above-described E. coli MGl 655 ΔybdA::cat can
be transferred to the E. coli L-cysteine-producing strain JM15(ydeD) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain JM15(ydeD)-ΔybdA.
E. coli JM15(ydeD) is a derivative of E. coli JM15 (US Patent No. 6,218,168), which can be transformed with DNA having the ydeD gene encoding a membrane protein, and is not involved in a biosynthetic pathway of any L-amino acid (U.S. Patent No. 5,972,663). The strain JMl 5 (CGSC# 5042) can be obtained from The Coli Genetic Stock Collection at the E. coli Genetic Resource Center, MCD Biology Department, Yale University (http://cgsc.biology.yale.edu/).
Fermentation conditions for evaluation of L-cysteine production were described in detail in Example 6 of US Patent No. 6,218,168.
Example 5. Production of L-leucine by E. coli 57- ΔvbdA
To test the effect of inactivation of the ybdA gene on L-leucine production, DNA fragments from the chromosome of the above-described E. coli strain MG1655 ΔybdA::cat can be transferred to the E. coli L-leucine-producing strain 57 (VKPM B-7386, US Patent No. 6,124,121) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain 57-pMW-ΔybdA. The strain 57 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on May 19, 1997 under accession number VKPM B-7386.
Both E. coli strains, 57 and 57-ΔybdA, can be cultured for 18-24 hours at 37°C on L- agar plates. To obtain a seed culture, the strains can be grown on a rotary shaker (250 rpm) at 320C for 18 hours in 20x200-mm test tubes containing 2 ml of L-broth supplemented with 4% sucrose. Then, the fermentation medium can be inoculated with 0.21 ml of seed material (10%). The fermentation can be performed in 2 ml of a minimal fermentation medium in 20x200-mm test tubes. Cells can be grown for 48-72 hours at 32°C with shaking at 250 rpm. The amount of L-leucine can be measured by paper chromatography (liquid phase composition: butanol - acetic acid - water = 4:1:1).
The composition of the fermentation medium (g/1) (pH 7.2) is as follows:
Glucose 60.0
(NH4)2SO4 25.0
K2HPO4 2.0
MgSO4-7H2O 1.0
Thiamine 0.01
CaCO3 25.0
Glucose and CaCO3 are sterilized separately.
Example 6. Production of L-histidine by E. coli 80-ΔybdA
To test the effect of inactivation of theybdA gene on L-histidine production, DNA fragments from the chromosome of the above-described E. coli MG1655 ΔybdA::cat can be transferred to the histidine-producing E. coli strain 80 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain strain 80-ΔybdA. The strain 80 has been described in Russian patent 2119536 and deposited in the Russian National Collection of Industrial Microorganisms (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on October 15, 1999 under accession number VKPM B- 7270 and then converted to a deposit under the Budapest Treaty on July 12, 2004.
Both E. coli strains, 80 and 80-ΔybdA, can each be cultured in L-broth for 6 h at 290C. Then, 0.1 ml of obtained culture can be inoculated into 2 ml of fermentation medium in a 20x200-mm test tube and cultivated for 65 hours at 290C with shaking on a rotary shaker (350 rpm). After cultivation, the amount of histidine which accumulates in the medium can be determined by paper chromatography. The paper can be developed with a mobile phase consisting of n-butanol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (0.5%) in acetone can be used as a visualizing reagent.
The composition of the fermentation medium (g/1) is as follows (pH 6.0):
Glucose 100.0
Mameno (soybean hydrolysate) 0.2 of as total nitrogen
L-proline 1.0
(NHU)2SO4 25.0
KH2PO4 2.0
MgSO4-7H20 1.0
FeSO4-7H20 0.01
MnSO4 0.01
Thiamine 0.001
Betaine 2.0
CaCO3 60.0
Glucose, proline, betaine and CaCO3 are sterilized separately. The pH is adjusted to 6.0 before sterilization.
Example 7. Production of L-glutamate by E. coli VL334thrC+-ΔvbdA To test the effect of inactivation of theybdA gene on L-glutamate production, DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ΔybdA::cat can be transferred to the E. coli L-glutamate-producing strain VL334thrC+ (EP 1172433) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor
Lab. Press, 1972, Plainview, NY) to obtain the strain VL334thrC+-ΔybdA The strain VL334thrC+ has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on December 6, 2004 under the accession number VKPM B-8961 and then converted to a deposit under the Budapest Treaty on December 8, 2004.
Both strains, VL334thrC+ and VL334thrC+-ΔybdA, can be grown for 18-24 hours at 370C on L-agar plates. Then, one loop of the cells can be transferred into test tubes containing 2ml of fermentation medium. The fermentation medium contains glucose (6OgA), ammonium sulfate (25 g/1), KH2PO4 (2g/l), MgSO4 (I g/1), thiamine (0.1 mg/ml), L-isoleucine (70 μg/ml), and CaCO3 (25 g/1). The pH is adjusted to 7.2. Glucose and CaCO3 are sterilized separately. Cultivation can be carried out at 30°C for 3 days with shaking. After the cultivation, the amount of L-glutamic acid which is produced can be determined by paper chromatography (liquid phase composition of butanol-acetic acid- water^: 1:1) with subsequent staining by ninhydrin (1% solution in acetone) and further elution of the compounds in 50% ethanol with 0.5% CdCl2.
Example 8. Production of L- phenylalanine by E. coli AJ12739-ΔvbdA
To test the effect of inactivation of the ybdA gene on L-phenylalanine production, DNA fragments from the chromosome of the above-described E. coli MG1655 ΔybdA::cat can be transferred to the phenylalanine-producing E. coli strain AJ12739 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain strain AJ12739-ΔybdA. The strain AJ12739 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on November 6, 2001 under accession no. VKPM B-8197 and then converted to a deposit under the Budapest Treaty on August 23, 2002.
Both strains, AJ12739-ΔybdA and AJ12739, can be cultivated at 37°C for 18 hours in a nutrient broth, and 0.3 ml of the obtained culture can each be inoculated into 3 ml of a fermentation medium in a 20x200-mm test tube and cultivated at 37°C for 48 hours with shaking on a rotary shaker. After cultivation, the amount of phenylalanine which accumulates in the medium can be determined by TLC. The 10x15 -cm TLC plates coated with 0.11 -mm layers of Sorbfil silica gel containing no fluorescent indicator (Stock Company Sorbpolymer, Krasnodar, Russia) can be used. The Sorbfil plates can be developed with a mobile phase consisting of propan-2-ol : ethylacetate : 25% aqueous ammonia : water = 40 : 40 : 7 : 16 (v/v). A solution of ninhydrin (2%) in acetone can be used as a visualizing reagent.
The composition of the fermentation medium (g/1) is as follows:
Glucose 40.0
(NEU)2SO4 16.0
K2HPO4 0.1
MgSO4-7H2O 1.0
FeSO4-7H2O 0.01
MnSO4-5H2O 0.01
Thiamine HCl 0.0002
Yeast extract 2.0
Tyrosine 0.125
CaCO3 20.0
Glucose and magnesium sulfate are sterilized separately. CaCO3 is dry-heat sterilized at 180° for 2 hours. The pH is adjusted to 7.0.
Example 9. Production of L- tryptophan by E. coli SVl 64 (pGH5V A vbdA To test the effect of inactivation of ϊhsybdA gene on L-tryptophan production, DNA fragments from the chromosome of the above-described E. coli strain MG1655 ΔybdA::cat can be transferred to the tryptophan-producing E. coli strain SV164 (pGH5) by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain SV164(pGH5)-ΔybdA. The strain SV164 has the trpE allele encoding anthranilate synthase free from feedback inhibition by tryptophan. The plasmid pGH5 harbors a mutant serA gene encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine. The strain SVl 64 (pGH5) was described in detail in US patent No. 6,180,373 or European patent 0662143.
Both strains, SV164(pGH5> ΔybdA and SV164(pGH5), can be cultivated with shaking at 37°C for 18 hours in 3 ml of nutrient broth supplemented with tetracycline (20 mg/1, marker of pGH5 plasmid). The obtained cultures (0.3 ml each) can each be inoculated into 3 ml of a fermentation medium containing tetracycline (20 mg/1) in 20 x 200-mm test tubes, and cultivated at 37°C for 48 hours with a rotary shaker at 250 rpm. After cultivation, the amount of tryptophan which accumulates in the medium can be determined by TLC as described in Example 8. The fermentation medium components are listed in Table 2, but should be sterilized in separate groups (A, B, C, D, E, F, and H), as shown, to avoid adverse interactions during sterilization.
Table 2
Group A had pH 7.1 adjusted by NH4OH. Each group is sterilized separately, chilled, and then mixed together.
Example 10. Production of L-proline by E. coli 702ilvA-ΔybdA To test the effect of inactivation oϊϋa&ybdA gene on L-proline production, DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ΔybdA::cat can be transferred to the proline-producing E. coli strain 702ilvA by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain the strain 702ilvA-ΔybdA. The strain 702ilvA has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on July 18, 2000 under accession number VKPM B-8012 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
Both E. coli strains, 702ilvA and 702ilvA-ΔybdA, can be grown for 18-24 hours at 37°C on L-agar plates. Then, these strains can be cultivated under the same conditions as in Example 8.
Example 11. Production of L-arginine by E. coli 382-ΔvbdA To test the effect of inactivation of theybdA gene on L-arginine production, DNA fragments from the chromosome of the above-described E. coli strain MGl 655 ΔybdA::cat
were transferred to the arginine-producing E. coli strain 382 by Pl transduction (Miller, J.H. Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, 1972, Plainview, NY) to obtain strain 382-ΔybdA. The strain 382 has been deposited in the Russian National Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) on April 10, 2000 under accession number VKPM B-7926 and then converted to a deposit under the Budapest Treaty on May 18, 2001.
Both strains, 382-ΔybdA and 382, were separately cultivated with shaking at 37°C for 18 hours in 3 ml of nutrient broth, and 0.3 ml of the obtained cultures was inoculated into 2 ml of a fermentation medium in 20 x 200-mm test tubes and cultivated at 32°C for 48 hours on a rotary shaker.
After the cultivation, the amount of L-arginine which accumulated in the medium was determined by paper chromatography using the following mobile phase: butanol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (2%) in acetone was used as a visualizing reagent. A spot containing L-arginine was cut out, L-arginine was eluted with 0.5% water solution of CdCl2, and the amount of L-arginine was estimated spectrophotometrically at 540 nm.
The results of 9 independent test tube fermentations are shown in Table 3. As follows from Table 3, 382-ΔybdA caused accumulation of a higher amount of L-arginine, as compared with 382.
The composition of the fermentation medium (g/1) was as follows:
Glucose 48.0
(NH4)2SO4 35.0
KH2PO4 2.0
MgSO4-7H2O 1.0
Thiamine HCl 0.0002
Yeast extract 1.0
L-isoleucine 0.1
CaCO3 5.0
Glucose and magnesium sulfate were sterilized separately. CaCO3 was dry-heat sterilized at 180°C for 2 hours. The pH was adjusted to 7.0.
Table 3
While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention. AU the cited references herein are incorporated as a part of this application by reference.
Industrial Applicability
According to the present invention, production of L-amino acid of a bacterium of the Enterobacteriaceae family can be enhanced.
Claims
1. An L-amino acid-producing bacterium of the Enter obacteriaceae family, wherein said bacterium has been modified to attenuate expression of the ybdA gene.
2. The bacterium according to claim 1, wherein said expression of the ybdA gene is attenuated by inactivation of the ybdA gene.
3. The bacterium according to claim 1, wherein said bacterium belongs to the genus
Escherichia.
4. The bacterium according to claim 1, wherein said bacterium belongs to the genus
Pantoea.
5. The L-amino acid-producing bacterium according to any of claims 1 to 4, wherein said
L-amino acid is selected from the group consisting of an aromatic L-amino acid and a non-aromatic L-amino acid.
6. The L-amino acid-producing bacterium according to claim 5, wherein said aromatic L- amino acid is selected from the group consisting of L-phenylalanine, L-tyrosine, and L- tryptophan.
7. The L-amino acid-producing bacterium according to claim 5, wherein said non-aromatic
L-amino acid is selected from the group consisting of L-threonine, L-lysine, L-cysteine, L-methionine, L-leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L- alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, and L- arginine.
8. A method for producing an L-amino acid comprising:
- cultivating the bacterium according to any of claims 1 to 7 in a medium, and
- collecting said L-amino acid from the medium.
9. The method according to claim 8, wherein said L-amino acid is selected from the group consisting of an aromatic L-amino acid and a non-aromatic L-amino acid.
10. The method according to claim 9, wherein said aromatic L-amino acid is selected from the group consisting of L-phenylalanine, L-tyrosine, and L-tryptophan.
11. The method according to claim 9, wherein said non-aromatic L-amino acid is selected from the group consisting of L-threonine, L-lysine, L-cysteine, L-methionine, L- leucine, L-isoleucine, L-valine, L-histidine, glycine, L-serine, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, L-proline, and L-arginine.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006112261 | 2006-04-13 | ||
RU2006112261/13A RU2333954C2 (en) | 2006-04-13 | 2006-04-13 | METHOD FOR OBTAINING L-THREONINE AND L-ARGININE USING BACTERIUM BELONGING TO GENUS Escherichia, IN WHICH GENE ybdA IS INACTIVATED |
US82970606P | 2006-10-17 | 2006-10-17 | |
US60/829,706 | 2006-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007119881A1 true WO2007119881A1 (en) | 2007-10-25 |
Family
ID=38180560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/058571 WO2007119881A1 (en) | 2006-04-13 | 2007-04-13 | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the ybda gene |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007119881A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112107A1 (en) * | 2000-11-04 | 2002-05-08 | Degussa | Preparing L-amino acids, particularly L-threonine, for use in pharmaceutical and in food industries, comprises employing the microorganisms of the Enterobacteriaceae family for fermentation in which the poxB gene is attenuated |
WO2003008616A2 (en) * | 2001-07-18 | 2003-01-30 | Degussa Ag | PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED aceK GENE |
EP1510582A1 (en) * | 2003-08-29 | 2005-03-02 | Ajinomoto Co., Inc. | Method for producing L-amino acid using bacterium of Enterobacteriaceae family, having nir operon inactivated |
-
2007
- 2007-04-13 WO PCT/JP2007/058571 patent/WO2007119881A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112107A1 (en) * | 2000-11-04 | 2002-05-08 | Degussa | Preparing L-amino acids, particularly L-threonine, for use in pharmaceutical and in food industries, comprises employing the microorganisms of the Enterobacteriaceae family for fermentation in which the poxB gene is attenuated |
WO2003008616A2 (en) * | 2001-07-18 | 2003-01-30 | Degussa Ag | PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED aceK GENE |
WO2003008600A2 (en) * | 2001-07-18 | 2003-01-30 | Degussa Ag | Process for the preparation of l-amino acids using strains of the enterobacteriaceae family |
EP1510582A1 (en) * | 2003-08-29 | 2005-03-02 | Ajinomoto Co., Inc. | Method for producing L-amino acid using bacterium of Enterobacteriaceae family, having nir operon inactivated |
Non-Patent Citations (2)
Title |
---|
FURRER J L ET AL: "Membrane protein P43 (entS) participates in enterobactin release from Escherichia coli", BIOSIS, 2003, XP002273738 * |
FURRER JASON L ET AL: "Export of the siderophore enterobactin in Escherichia coli: Involvement of a 43 kDa membrane exporter", MOLECULAR MICROBIOLOGY, vol. 44, no. 5, June 2002 (2002-06-01), pages 1225 - 1234, XP002440399, ISSN: 0950-382X * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7919283B2 (en) | Method for producing an L-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of any of the cynT, cynS, cynX or cynR gene or combination thereof | |
US7888077B2 (en) | Method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family with attenuated expression of the kefB gene | |
EP2007873A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE sfmACDFH-fimZ CLUSTER OR THE fimZ GENE | |
US7794988B2 (en) | Method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family with attenuated expression of the rspAB operon | |
US8691537B2 (en) | Method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family with attenuated expression of the rcsA gene | |
EP1856243B1 (en) | Process for producing an l-amino acid employing a bacterium of the enterobacteriaceae family with attenuated leuo expression | |
EP1929027A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE ybiV GENE | |
EP1848810A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family having expression of the bola gene attenuated | |
WO2007119891A9 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE fhuA GENE | |
US20100143982A1 (en) | METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE aldH GENE | |
EP1856242B1 (en) | Process for producing a l-amino acid employing a bacterium of the enterobacteriaceae family with attenuated nac expression | |
WO2008096837A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the tolc gene | |
WO2006123763A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the dicb and/or dicf gene | |
WO2008105276A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE ycbPONME OPERON (ssuEADCB OPERON) | |
WO2009014259A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE yncD GENE | |
WO2007083788A1 (en) | A method for producing an l-amino acid using a bacterium of enterobacteriaceae family with attenuated expression of the lrha gene | |
WO2007083789A1 (en) | A method for producing an l-amino acid using a bacterium of enterobacteriaceae family with attenuated expression of the yfeh gene | |
WO2007119881A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the ybda gene | |
WO2008004682A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the yrah-r cluster | |
WO2007086547A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE yrbG GENE | |
WO2007139220A1 (en) | A method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated expression of the yehabcde cluster | |
WO2009022755A1 (en) | METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ATTENUATED EXPRESSION OF THE chaC GENE | |
WO2006098393A2 (en) | Method for producing an l-amino acid using a bacterium of the enterobacteriaceae family with attenuated sana expression | |
WO2007086544A1 (en) | A method for producing an l-amino acid using a bacterium of enterobacteriaceae family with attenuated expression of the bisc gene | |
WO2012011595A1 (en) | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY HAVING ATTENUATED EXPRESSION OF THE astCADBE OPERON |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07742007 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07742007 Country of ref document: EP Kind code of ref document: A1 |